<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>EN Abasaglar WS1587 PI (pre opinion)(25.06.20)</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"MT Extra";
	panose-1:5 5 1 2 1 2 5 2 2 2;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:Leelawadee;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Uighur";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Alef;}
@font-face
	{font-family:"Amasis MT Pro";}
@font-face
	{font-family:"Amasis MT Pro Black";}
@font-face
	{font-family:"Amasis MT Pro Light";}
@font-face
	{font-family:"Amasis MT Pro Medium";}
@font-face
	{font-family:"Amatic SC";}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Aref Ruqaa";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:Assistant;}
@font-face
	{font-family:"Assistant ExtraBold";}
@font-face
	{font-family:"Assistant ExtraLight";}
@font-face
	{font-family:"Assistant Light";}
@font-face
	{font-family:"Assistant SemiBold";}
@font-face
	{font-family:Athiti;}
@font-face
	{font-family:"Athiti ExtraLight";}
@font-face
	{font-family:"Athiti Light";}
@font-face
	{font-family:"Athiti Medium";}
@font-face
	{font-family:"Athiti SemiBold";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Demi";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Bierstadt;}
@font-face
	{font-family:"Bierstadt Display";}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Charmonman;}
@font-face
	{font-family:Chonburi;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"EB Garamond";}
@font-face
	{font-family:"EB Garamond ExtraBold";}
@font-face
	{font-family:"EB Garamond Medium";}
@font-face
	{font-family:"EB Garamond SemiBold";}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:Fahkwang;}
@font-face
	{font-family:"Fahkwang ExtraLight";}
@font-face
	{font-family:"Fahkwang Light";}
@font-face
	{font-family:"Fahkwang Medium";}
@font-face
	{font-family:"Fahkwang SemiBold";}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:"Frank Ruhl Libre";}
@font-face
	{font-family:"Frank Ruhl Libre Black";}
@font-face
	{font-family:"Frank Ruhl Libre Light";}
@font-face
	{font-family:"Frank Ruhl Libre Medium";}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:"Goudy Type";}
@font-face
	{font-family:Grandview;}
@font-face
	{font-family:"Grandview Display";}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:Heebo;}
@font-face
	{font-family:"Heebo Black";}
@font-face
	{font-family:"Heebo ExtraBold";}
@font-face
	{font-family:"Heebo Light";}
@font-face
	{font-family:"Heebo Medium";}
@font-face
	{font-family:"Heebo Thin";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:Krub;}
@font-face
	{font-family:"Krub ExtraLight";}
@font-face
	{font-family:"Krub Light";}
@font-face
	{font-family:"Krub Medium";}
@font-face
	{font-family:"Krub SemiBold";}
@font-face
	{font-family:Lalezar;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Miriam Libre";}
@font-face
	{font-family:Mitr;}
@font-face
	{font-family:"Mitr ExtraLight";}
@font-face
	{font-family:"Mitr Light";}
@font-face
	{font-family:"Mitr Medium";}
@font-face
	{font-family:"Mitr SemiBold";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Open Sans";}
@font-face
	{font-family:"Open Sans ExtraBold";}
@font-face
	{font-family:"Open Sans Light";}
@font-face
	{font-family:"Open Sans SemiBold";}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:Pridi;}
@font-face
	{font-family:"Pridi ExtraLight";}
@font-face
	{font-family:"Pridi Light";}
@font-face
	{font-family:"Pridi Medium";}
@font-face
	{font-family:"Pridi SemiBold";}
@font-face
	{font-family:Prompt;}
@font-face
	{font-family:"Prompt Black";}
@font-face
	{font-family:"Prompt ExtraBold";}
@font-face
	{font-family:"Prompt ExtraLight";}
@font-face
	{font-family:"Prompt Light";}
@font-face
	{font-family:"Prompt Medium";}
@font-face
	{font-family:"Prompt SemiBold";}
@font-face
	{font-family:"Prompt Thin";}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Reem Kufi";}
@font-face
	{font-family:Roboto;}
@font-face
	{font-family:"Roboto Black";}
@font-face
	{font-family:"Roboto Condensed";}
@font-face
	{font-family:"Roboto Condensed Light";}
@font-face
	{font-family:"Roboto Condensed Medium";}
@font-face
	{font-family:"Roboto Light";}
@font-face
	{font-family:"Roboto Medium";}
@font-face
	{font-family:"Roboto Thin";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Seaford;}
@font-face
	{font-family:"Seaford Display";}
@font-face
	{font-family:"Secular One";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:Skeena;}
@font-face
	{font-family:"Skeena Display";}
@font-face
	{font-family:"Source Code Pro";}
@font-face
	{font-family:"Source Code Pro Black";}
@font-face
	{font-family:"Source Code Pro ExtraLight";}
@font-face
	{font-family:"Source Code Pro Light";}
@font-face
	{font-family:"Source Code Pro Medium";}
@font-face
	{font-family:"Source Code Pro Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Source Serif Pro";}
@font-face
	{font-family:"Source Serif Pro Black";}
@font-face
	{font-family:"Source Serif Pro ExtraLight";}
@font-face
	{font-family:"Source Serif Pro Light";}
@font-face
	{font-family:"Source Serif Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"Suez One";}
@font-face
	{font-family:Tenorite;}
@font-face
	{font-family:"Tenorite Display";}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:Trirong;}
@font-face
	{font-family:"Trirong Black";}
@font-face
	{font-family:"Trirong ExtraBold";}
@font-face
	{font-family:"Trirong ExtraLight";}
@font-face
	{font-family:"Trirong Light";}
@font-face
	{font-family:"Trirong Medium";}
@font-face
	{font-family:"Trirong SemiBold";}
@font-face
	{font-family:"Trirong Thin";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	page-break-after:avoid;
	background:#993366;
	font-size:14.0pt;
	font-family:"Arial",sans-serif;
	color:white;
	layout-grid-mode:line;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:18.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,- H19\,Annotationtext\,Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char\,Tekst opmerking";
	mso-style-link:"Comment Text Char\,- H19 Char\,Annotationtext Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char1\,Comment Text Char1 Char Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
span.MsoCommentReference
	{mso-style-name:"Comment Reference\,Annotationmark";}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:.8in;
	margin-bottom:0in;
	margin-left:.8in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:#4F81BD;
	font-style:italic;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
em
	{font-weight:bold;
	font-style:normal;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,- H19 Char\,Annotationtext Char\,Char Char\,Comment Text Char Char Char\,Comment Text Char Char Char Char Char\,Comment Text Char Char1 Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char1\,Comment Text Char1 Char Char Char";
	mso-style-link:"Comment Text\,- H19\,Annotationtext\,Char\,Comment Text Char Char\,Comment Text Char Char Char Char\,Comment Text Char Char1\,Comment Text Char Char1 Char\,Comment Text Char1 Char\,Comment Text Char1 Char Char\,Comment Text Char2 Char\,Tekst opmerking";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
p.PIbodytext, li.PIbodytext, div.PIbodytext
	{mso-style-name:"PI body text";
	mso-style-link:"PI body text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.PIbodytextChar
	{mso-style-name:"PI body text Char";
	mso-style-link:"PI body text";
	font-family:"Times New Roman",serif;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Arial",sans-serif;
	color:white;
	background:#993366;
	layout-grid-mode:both;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;
	color:black;}
p.IFUBodyText, li.IFUBodyText, div.IFUBodyText
	{mso-style-name:"IFU Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.IFUBulletedBodyText, li.IFUBulletedBodyText, div.IFUBulletedBodyText
	{mso-style-name:"IFU Bulleted Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.IFUBulletedBodyText2, li.IFUBulletedBodyText2, div.IFUBulletedBodyText2
	{mso-style-name:"IFU Bulleted Body Text 2";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:black;}
p.TittleB, li.TittleB, div.TittleB
	{mso-style-name:"Tittle B";
	mso-style-link:"Tittle B Char";
	margin-top:0in;
	margin-right:6.0pt;
	margin-bottom:0in;
	margin-left:6.35pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.TittleBChar
	{mso-style-name:"Tittle B Char";
	mso-style-link:"Tittle B";
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.mdTblEntry, li.mdTblEntry, div.mdTblEntry
	{mso-style-name:"md_Tbl Entry";
	margin:0in;
	line-height:12.95pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.IFUHeading1, li.IFUHeading1, div.IFUHeading1
	{mso-style-name:"IFU Heading 1";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:black;
	layout-grid-mode:line;
	font-weight:bold;}
p.a, li.a, div.a
	{mso-style-name:a;
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.KommentarerChar
	{mso-style-name:"Kommentarer Char";}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:#65B4B4;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:#FF4B4B;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection3
	{page:WordSection3;}
@page WordSection4
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection4
	{page:WordSection4;}
@page WordSection5
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection5
	{page:WordSection5;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>1. NAME OF </span></b><b><span lang=EN-GB>THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR</span><span lang=EN-GB> 100&nbsp;units/mL solution for
injection in a cartridge</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Each mL
contains 100&nbsp;units insulin glargine* (equivalent to 3.64&nbsp;mg). </span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each cartridge contains 3&nbsp;mL of solution for injection,
equivalent to 300&nbsp;units. </span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>*produced by recombinant DNA technology in <i>Escherichia coli</i>. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For the full list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solution for
injection (injection).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear,
colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4. </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment of diabetes mellitus in adults, adolescents and children
aged 2&nbsp;years and above.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2 Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR contains insulin glargine, an insulin analogue and has a
prolonged duration of action. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR should be administered once daily at any time but at the
same time each day. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The dose regimen (dose and timing) should be individually adjusted.
In patients with type&nbsp;2 diabetes mellitus, ABASAGLAR can also be given
together with orally active antidiabetic medicinal products. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The potency of this medicinal product is stated in units. These
units are exclusive to insulin glargine and are not the same as IU or the units
used to express the potency of other insulin analogues (see section 5.1). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Elderly population (&#8805;65 years old)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the elderly, progressive deterioration of renal function may lead
to a steady decrease in insulin requirements.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients with renal impairment, insulin requirements
may be diminished due to reduced insulin metabolism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In patients with hepatic impairment, insulin requirements may be
diminished due to reduced capacity for gluconeogenesis and reduced insulin
metabolism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Adolescents and children aged 2 years and older</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of insulin glargine have been established in
adolescents and children aged 2&nbsp;years and older (see section 5.1). The
dose regimen (dose and timing) should be individually adjusted. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children below 2 years of age</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of insulin glargine have not been
established No data are available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Switch from other insulins to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>When switching from
a treatment regimen with an intermediate or long-acting insulin to a regimen
with ABASAGLAR, a change of the dose of the basal insulin may be required and
the concomitant antidiabetic treatment may need to be adjusted (dose and timing
of additional regular insulins or fast-acting insulin analogues or the dose of
oral antidiabetic medicinal products). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Switch from twice daily NPH insulin to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To reduce the risk of nocturnal and early morning hypoglycaemia,
patients who are changing their basal insulin regimen from a twice daily NPH
insulin to a once daily regimen with ABASAGLAR should reduce their daily dose
of basal insulin by 20-30&nbsp;% during the first weeks of treatment. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Switch
from insulin glargine 300 units/ml to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR and
Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly
interchangeable. To reduce the risk of hypoglycemia, patients who are changing
their basal insulin regimen from an insulin regimen with once daily insulin
glargine 300 units/ml to a once daily regimen with ABASAGLAR should reduce
their dose by approximately 20%.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>During the first weeks the reduction should, at least partially, be
compensated by an increase in mealtime insulin, after this period the regimen
should be adjusted individually. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Close metabolic monitoring is recommended during the switch and in
the initial weeks thereafter. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>With improved metabolic control and resulting increase in insulin
sensitivity a further adjustment in dose regimen may become necessary. Dose
adjustment may also be required, for example, if the patient's weight or
life-style changes, change of timing of insulin dose or other circumstances
arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see
section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients with high insulin doses because of antibodies to human
insulin may experience an improved insulin response with ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is administered subcutaneously.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR should not be administered intravenously. The prolonged
duration of action of insulin glargine is dependent on its injection into
subcutaneous tissue. Intravenous administration of the usual subcutaneous dose
could result in severe hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>There are no clinically relevant differences in serum insulin or
glucose levels after abdominal, deltoid or thigh administration of insulin
glargine. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Injection sites should always be rotated within the same region in
order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see
section 4.4 and 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR must not be mixed with any other insulin or diluted.
Mixing or diluting can change its time/action profile and mixing can cause
precipitation. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For further details on handling, see section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In order to
improve the traceability of biological medicinal products, the name and the
batch number of the administered product should be clearly recorded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Diabetic ketoacidosis</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is not the insulin of choice for the treatment of diabetic
ketoacidosis. Instead, regular insulin administered intravenously is
recommended in such cases. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Hlk38983853"><u><span lang=EN-GB>Insulin requirements and dose
adjustments</span></u></a></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In case of insufficient glucose control or a tendency to hyperglycaemic
or hypoglycaemic episodes, the patient's adherence to the prescribed treatment
regimen, injection sites and proper injection technique and all other relevant
factors must be reviewed before dose adjustment is considered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Transferring a patient to another type or brand of insulin should be
done under strict medical supervision. Changes in strength, brand
(manufacturer), type (regular, NPH, lente, long&#8209;acting, etc.), origin
(animal, human, human insulin analogue) and/or method of manufacture may result
in the need for a change in dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Hypoglycaemia</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The time of occurrence of hypoglycaemia depends on the action
profile of the insulins used and may, therefore, change when the treatment
regimen is changed. Due to more sustained basal insulin supply with insulin
glargine, less nocturnal but more early morning hypoglycaemia can be expected.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised, and intensified blood
glucose monitoring is advisable in patients in whom hypoglycaemic episodes
might be of particular clinical relevance, such as in patients with significant
stenoses of the coronary arteries or of the blood vessels supplying the brain
(risk of cardiac or cerebral complications of hypoglycaemia) as well as in
patients with proliferative retinopathy, particularly if not treated with
photocoagulation (risk of transient amaurosis following hypoglycaemia). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be aware of circumstances where warning symptoms of
hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be
changed, be less pronounced or be absent in certain risk groups. These include
patients:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom glycaemic control
is markedly improved,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom hypoglycaemia
develops gradually,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  who are elderly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  after transfer from
animal insulin to human insulin,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom an autonomic
neuropathy is present,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  with a long history of
diabetes,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  suffering from a
psychiatric illness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  receiving concurrent
treatment with certain other medicinal products (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Such situations may result in severe hypoglycaemia (and possibly
loss of consciousness) prior to the patient's awareness of hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The prolonged effect of subcutaneous insulin glargine may delay
recovery from hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If normal or decreased values for glycated haemoglobin are noted,
the possibility of recurrent, unrecognised (especially nocturnal) episodes of
hypoglycaemia must be considered. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Adherence of the patient to the dose and dietary regimen, correct
insulin administration and awareness of hypoglycaemia symptoms are essential to
reduce the risk of hypoglycaemia. Factors increasing the susceptibility to
hypoglycaemia require particularly close monitoring and may necessitate dose
adjustment. These include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  change in the injection
area,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  improved insulin
sensitivity (e.g., by removal of stress factors),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  unaccustomed, increased
or prolonged physical activity,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  intercurrent illness
(e.g. vomiting, diarrhoea),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  inadequate food intake,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  missed meals,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  alcohol consumption,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  certain uncompensated
endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or
adrenocortical insufficiency),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  concomitant treatment
with certain other medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Injection
technique</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients must be instructed to perform
continuous rotation of the injection site to reduce the risk of developing
lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed
insulin absorption and worsened glycaemic control following insulin injections
at sites with these reactions. A sudden change in the injection site to an
unaffected area has been reported to result in hypoglycaemia. Blood glucose
monitoring is recommended after the change in the injection site, and dose
adjustment of antidiabetic medications may be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Intercurrent illness</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Intercurrent illness requires intensified metabolic monitoring. In
many cases urine tests for ketones are indicated, and often it is necessary to
adjust the insulin dose. The insulin requirement is often increased. Patients
with type&nbsp;1 diabetes must continue to consume at least a small amount of
carbohydrates on a regular basis, even if they are able to eat only little or
no food, or are vomiting etc. and they must never omit insulin entirely. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Insulin antibodies</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin administration may cause insulin antibodies to form. In rare
cases, the presence of such insulin antibodies may necessitate adjustment of
the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see
section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Pens to be used with ABASAGLAR cartridges </span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The cartridges should only be used in conjunction with a Lilly reusable
insulin pen and should not be used with any other reusable pen as the dosing
accuracy has not been established with other pens. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Medication errors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medication
errors have been reported in which other insulins, particularly short&#8209;acting
insulins, have been accidentally administered instead of insulin glargine.
Insulin label must always be checked before each injection to avoid medication
errors between ABASAGLAR and other insulins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Combination of ABASAGLAR with pioglitazone</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of cardiac
failure have been reported when pioglitazone was used in combination with
insulin, especially in patients with risk factors for development of cardiac
heart failure. This should be kept in mind if treatment with the combination of
pioglitazone and ABASAGLAR is considered. If the combination is used, patients
should be observed for signs and symptoms of heart failure, weight gain and
oedema. Pioglitazone should be discontinued if any deterioration in cardiac
symptoms occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Sodium
content</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains less than 1&nbsp;mmol sodium
(23&nbsp;mg) per dose, i.e., essentially sodium&#8209;free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A number of substances affect glucose metabolism and may require
dose adjustment of insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Substances that may enhance the blood-glucose&#8209;lowering effect
and increase susceptibility to hypoglycaemia include oral antidiabetic
medicinal products, angiotensin converting enzyme (ACE) inhibitors,
disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,
pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide
antibiotics. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Substances that may reduce the blood-glucose-lowering effect include
corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,
oestrogens, progestogens, phenothiazine derivatives, somatropin,
sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.
clozapine and olanzapine) and protease inhibitors. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Beta-blockers, clonidine, lithium salts or alcohol may either
potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine
may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In addition, under the influence of sympatholytic medicinal products
such as beta-blockers, clonidine, guanethidine and reserpine, the signs of
adrenergic counter-regulation may be reduced or absent.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6 </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For insulin glargine no clinical data on exposed pregnancies from
controlled clinical studies are available. A large amount of data on pregnant
women (more than 1,000&nbsp;pregnancy outcomes) indicate no specific adverse
effects of insulin glargine on pregnancy and no specific malformative nor
feto/neonatal toxicity of insulin glargine. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:lime'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal data do not indicate reproductive toxicity. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The use of ABASAGLAR may be considered during pregnancy, if clinically
needed. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is essential for patients with pre-existing or gestational
diabetes to maintain good metabolic control throughout pregnancy to prevent
adverse outcomes associated with hyperglycaemia. Insulin requirements may
decrease during the first trimester and generally increase during the second
and third trimesters. Immediately after delivery, insulin requirements decline
rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose
control is essential. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is unknown whether insulin glargine is excreted in human milk. No
metabolic effects of ingested insulin glargine on the breast&#8209;fed
newborn/infant are anticipated since insulin glargine as a peptide is digested
into amino acids in the human gastrointestinal tract. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Breast-feeding women may require adjustments in insulin dose and
diet. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal studies do not indicate direct harmful effects with respect
to fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7 Effects on ability
to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The patient's ability to concentrate and react may be
impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a
result of visual impairment. This may constitute a risk in situations where
these abilities are of special importance (e.g. driving a car or using machines).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be advised to take precautions to avoid
hypoglycaemia whilst driving. This is particularly important in those who have
reduced or absent awareness of the warning symptoms of hypoglycaemia or have
frequent episodes of hypoglycaemia. It should be considered whether it is
advisable to drive or operate machines in these circumstances.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.8 Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Summary of safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypoglycaemia (very common), in general the most frequent adverse
reaction of insulin therapy, may occur if the insulin dose is too high in
relation to the insulin requirement (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The following related adverse reactions from clinical trials
are listed below as MedDRA preferred term by system organ class and in order of
decreasing incidence (very common: &#8805;1/10; common: &#8805;1/100 to
&lt;1/10; uncommon: &#8805;1/1,000 to &lt;1/100; rare: &#8805;1/10,000 to
&lt;1/1,000; very rare: &lt;1/10,000<span style='color:black'> and not known
(cannot be estimated from the available data</span>).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Within each frequency grouping, adverse reactions are presented in
order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='margin-left:12.5pt;border-collapse:collapse;border:none'>
 <tr style='height:16.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>MedDRA system organ classes</span></b></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Very common</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Common</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Uncommon</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Rare</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Very rare</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal'><b><span
  lang=EN-GB>Not known</span></b></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Immune system disorders </span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:16.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Allergic reactions</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:16.75pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Hypoglycaemia</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Nervous system disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:11.0pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Dysgeusia</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.0pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Eyes disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Visual impairment </span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Retinopathy</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Lipohypertrophy</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Lipoatrophy</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Cutaneous amyloidosis</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width="12%" style='width:12.96%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Myalgia</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=6 valign=top style='width:87.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>General disorders and administration site conditions</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Injection site reactions</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="23%" valign=top style='width:23.04%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Oedema</span></p>
  </td>
  <td width="15%" valign=top style='width:15.4%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.32%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.84%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="10%" valign=top style='width:10.76%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.66%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.96%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>Metabolism and nutrition disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Severe hypoglycaemic attacks, especially if recurrent,
may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may
be life-threatening. In many patients, the signs and symptoms of
neuroglycopenia are preceded by signs of adrenergic counter-regulation.
Generally, the greater and more rapid the decline in blood glucose, the more
marked is the phenomenon of counter-regulation and its symptoms.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Immune system disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Immediate-type allergic reactions to insulin are rare. Such
reactions to insulin (including insulin glargine) or the excipients may, for
example, be associated with generalised skin reactions, angio-oedema,
bronchospasm, hypotension and shock, and may be life-threatening.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Eyes disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A marked change in glycaemic control may cause temporary visual
impairment, due to temporary alteration in the turgidity and refractive index
of the lens.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Long-term improved glycaemic control decreases the risk of
progression of diabetic retinopathy. However, intensification of insulin
therapy with abrupt improvement in glycaemic control may be associated with
temporary worsening of diabetic retinopathy. In patients with proliferative
retinopathy, particularly if not treated with photocoagulation, severe
hypoglycaemic episodes may result in transient amaurosis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Skin and subcutaneous tissue disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lipodystrophy and cutaneous amyloidosis may occur at the injection
site and delay local insulin absorption. Continuous rotation of the injection
site within the given injection area may help to reduce or prevent these reactions
(see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>General disorders and administration site conditions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Injection site reactions include redness, pain, itching, hives,
swelling, or inflammation. Most minor reactions to insulins at the injection
site usually resolve in a few days to a few weeks. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rarely, insulin may cause sodium retention and oedema particularly
if previously poor metabolic control is improved by intensified insulin
therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In general, the safety profile for children and adolescents (&#8804;&nbsp;18&nbsp;years
of age) is similar to the safety profile for adults. The adverse reaction
reports received from post marketing surveillance included relatively more
frequent injection site reactions (injection site pain, injection site
reaction) and skin reactions (rash, urticaria) in children and adolescents
(&#8804;&nbsp;18&nbsp;years of age) than in adults. Clinical study safety data
are not available for children under 2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin overdose may lead to severe and sometimes long-term and
life-threatening hypoglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Management</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Mild episodes of hypoglycaemia can usually be treated
with oral carbohydrates. Adjustments in dose of the medicinal product, meal
patterns, or physical activity may be needed. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>More severe episodes with coma, seizure, or neurologic impairment
may be treated with intramuscular/subcutaneous glucagon or concentrated
intravenous glucose. Sustained carbohydrate intake and observation may be
necessary because hypoglycaemia may recur after apparent clinical recovery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>5.1  Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Drugs used in diabetes, insulins and analogues for injection,
long-acting. ATC Code: A10AE04.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR is a
biosimilar medicinal product. Detailed information is available on the website
of the European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
is a human insulin analogue designed to have a low solubility at neutral pH. It
is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH&nbsp;4).
After injection into the subcutaneous tissue, the acidic solution is
neutralised leading to formation of micro-precipitates from which small amounts
of insulin glargine are continuously released, providing a smooth, peakless,
predictable concentration/time profile with a prolonged duration of action.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
is metabolised into 2 active metabolites M1 and M2 (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Insulin
receptor binding</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies indicate that the affinity of insulin glargine and its
metabolites M1 and M2 for the human insulin receptor is similar to the one of
human insulin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IGF-1 receptor
binding: The affinity of insulin glargine for the human IGF-1 receptor is
approximately 5 to 8-fold greater than that of human insulin (but approximately
70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1
receptor with slightly lower affinity compared to human insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The total therapeutic insulin concentration (insulin glargine and
its metabolites) found in type&nbsp;1 diabetic patients was markedly lower than
what would be required for a half maximal occupation of the IGF-1 receptor and
the subsequent activation of the mitogenic-proliferative pathway initiated by the
IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate
the mitogenic-proliferative pathway; however, the therapeutic concentrations
found in insulin therapy, including in ABASAGLAR therapy, are considerably
lower than the pharmacological concentrations required to activate the IGF-1
pathway. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
activity of insulin, including insulin glargine, is regulation of glucose
metabolism. Insulin and its analogues lower blood glucose levels by stimulating
peripheral glucose uptake, especially by skeletal muscle and fat, and by
inhibiting hepatic glucose production. Insulin inhibits lipolysis in the
adipocyte, inhibits proteolysis and enhances protein synthesis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
pharmacology studies, intravenous insulin glargine and human insulin have been
shown to be equipotent when given at the same doses. As with all insulins, the
time course of action of insulin glargine may be affected by physical activity
and other variables.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In euglycaemic
clamp studies in healthy subjects or in patients with type&nbsp;1 diabetes, the
onset of action of subcutaneous insulin glargine was slower than with human NPH
insulin, its effect profile was smooth and peakless, and the duration of its
effect was prolonged.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
graph shows the results from a study in patients:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Figure 1: </span></b><b>Activity profile in patients with type</b><span
lang=EN-GB>&nbsp;</span><b>1 diabetes</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=right style='text-align:right;line-height:normal;
page-break-after:avoid'><span style='position:absolute;z-index:251682816;
left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px'><img
width=652 height=274 src="ABASAGLAR_clean_files/image002.png"></span><span
style='position:absolute;z-index:251680768;left:0px;margin-left:161px;
margin-top:233px;width:159px;height:39px'><img width=159 height=39
src="ABASAGLAR_clean_files/image003.png" alt="Time (h) after s.c injection"></span><span
lang=EN-GB><img border=0 width=590 height=286
src="ABASAGLAR_clean_files/image004.jpg"></span></p>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>* Determined as
amount of glucose infused to maintain constant plasma glucose levels (hourly
mean values)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The longer
duration of action of subcutaneous insulin glargine is directly related to its
slower rate of absorption and supports once daily administration. The time
course of action of insulin and insulin analogues such as insulin glargine may
vary considerably in different individuals or within the same individual</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a clinical
study, symptoms of hypoglycaemia or counter-regulatory hormone responses were
similar after intravenous insulin glargine and human insulin both in healthy
volunteers and patients with type&nbsp;1 diabetes.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Clinical safety and efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
studies, antibodies that cross-react with human insulin and insulin glargine
were observed with the same frequency in both NPH-insulin and insulin glargine
treatment groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Effects of
insulin glargine (once daily) on diabetic retinopathy were evaluated in an
open-label 5&nbsp;year NPH-controlled study (NPH given bid) in 1024 type&nbsp;2
diabetic patients in which progression of retinopathy by 3 or more steps on the
Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by
fundus photography. No significant difference was seen in the progression of
diabetic retinopathy when insulin glargine was compared to NPH insulin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The ORIGIN
(Outcome Reduction with Initial Glargine INtervention) study was a multicenter,
randomised, 2x2 factorial design study conducted in 12,537 participants at high
cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired
glucose tolerance (IGT) (12% of participants) or type&nbsp;2 diabetes mellitus
treated with &#8804;1 antidiabetic oral agent (88% of participants).
Participants were randomised (1:1) to receive insulin glargine (n=6,264),
titrated to reach FPG &#8804;95 mg/dL (5.3 mM), or standard care (n=6,273).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The first
co-primary efficacy outcome was the time to the first occurrence of CV death,
nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary
efficacy outcome was the time to the first occurrence of any of the first
co-primary events, or revascularisation procedure (coronary, carotid, or
peripheral), or hospitalisation for heart failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Secondary
endpoints included all-cause mortality and a composite microvascular outcome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
did not alter the relative risk for CV disease and CV mortality when compared
to standard of care. There were no differences between insulin glargine and
standard care for the two co-primary outcomes; for any component endpoint
comprising these outcomes; for all-cause mortality; or for the composite
microvascular outcome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mean dose of
insulin glargine by study end was 0.42 U/kg. At baseline, participants had a
median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9
to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care
group throughout the duration of follow-up. The rates of severe hypoglycaemia
(affected participants per 100 participant years of exposure) were 1.05 for
insulin glargine and 0.30 for standard care group and the rates of confirmed
non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard
care group. Over the course of this 6-year study, 42% of the insulin glargine
group did not experience any hypoglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At the last
on-treatment visit, there was a mean increase in body weight from baseline of
1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the
standard care group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a randomised,
controlled clinical study, paediatric patients (age range 6 to 15&nbsp;years)
with type&nbsp;1 diabetes (n=349) were treated for 28&nbsp;weeks with a
basal-bolus insulin regimen where regular human insulin was used before each
meal. Insulin glargine was administered once daily at bedtime and NPH human
insulin was administered once or twice daily. Similar effects on
glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed
in both treatment groups, however fasting plasma glucose decreased more from
baseline in the insulin glargine group than in the NPH group. There was less
severe hypoglycaemia in the insulin glargine group as well. One hundred forty
three of the patients treated with insulin glargine in this study continued
treatment with insulin glargine in an uncontrolled extension study with mean
duration of follow-up of 2&nbsp;years. No new safety signals were seen during
this extended treatment with insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A crossover
study comparing insulin glargine plus lispro insulin to NPH plus regular human
insulin (each treatment administered for 16 weeks in random order) in 26
adolescent type&nbsp;1 diabetic patients aged 12 to 18&nbsp;years was also
performed. As in the paediatric study described above, fasting plasma glucose
reduction from baseline was greater in the insulin glargine group than in the
NPH group. HbA<sub>1c</sub> changes from baseline were similar between treatment
groups; however blood glucose values recorded overnight were significantly
higher in the insulin glargine/ lispro group than the NPH/regular group, with a
mean nadir of 5.4&nbsp;mM vs. 4.1&nbsp;mM. Correspondingly, the incidences of
nocturnal hypoglycaemia were 32&nbsp;% in the insulin glargine / lispro group
vs. 52&nbsp;% in the NPH / regular group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A 24-week
parallel group study was conducted in 125 children with type&nbsp;1 diabetes
mellitus aged 2 to 6&nbsp;years, comparing insulin glargine given once daily in
the morning to NPH insulin given once or twice daily as basal insulin. Both
groups received bolus insulin before meals. The primary aim of demonstrating
non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and
there was a trend to an increase of hypoglycaemic events with insulin glargine
[insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin
and glucose variabilities were comparable in both treatment groups. No new
safety signals were observed in this trial.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2 Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In healthy subjects and diabetic patients, insulin serum
concentrations indicated a slower and much more prolonged absorption and showed
a lack of a peak after subcutaneous injection of insulin glargine in comparison
to human NPH insulin. Concentrations were thus consistent with the time profile
of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the
activity profiles over time of insulin glargine and NPH insulin. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin glargine injected once daily will reach steady state levels
in 2-4 days after the first dose. </span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>After subcutaneous injection in diabetic patients, insulin glargine
is rapidly metabolised at the carboxyl terminus of the Beta chain with
formation of two active metabolites M1 (21A-Gly-insulin) and M2
(21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is
the metabolite M1. The exposure to M1 increases with the administered dose of insulin
glargine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetic and pharmacodynamic findings indicate that the
effect of the subcutaneous injection with insulin glargine is principally based
on exposure to M1. Insulin glargine and the metabolite M2 were not detectable
in the vast majority of subjects and, when they were detectable their
concentration was independent of the administered dose of insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>When given intravenously the elimination half-life of insulin
glargine and human insulin were comparable. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt'>Special populations</span></u></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In clinical
studies, subgroup analyses based on age and gender did not indicate any
difference in safety and efficacy in insulin glargine-treated patients compared
to the entire study population.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pharmacokinetics in children aged 2 to less than 6 years with type&nbsp;1
diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma
trough levels of insulin glargine and its main M1 and M2 metabolites were
measured in children treated with insulin glargine, revealing plasma
concentration patterns similar to adults, and providing no evidence for
accumulation of insulin glargine or its metabolites with chronic dosing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Non-clinical data reveal no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity, carcinogenic potential, toxicity to reproduction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.1  List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Zinc oxide</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Metacresol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Glycerol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Sodium hydroxide (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.2  Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product must not be mixed with other medicinal
products. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.3  Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>2 years.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Shelf life after first use </span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The medicinal product may be stored for a maximum of 28&nbsp;days up
to 30C and away from direct heat or direct light. Pens in use must not be
stored in the refrigerator. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pen cap must be put back on the pen after each injection in
order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.4  Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Before use</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2C - 8C).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not store ABASAGLAR next to the freezer compartment or a freezer
pack.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep the cartridge in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>In use </span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For storage conditions after first opening of this medicinal
product, see section 6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.5  Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><s><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>3 mL solution in a cartridge (type&nbsp;1 colourless glass) with a
plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl
rubber) with aluminium seal.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.6  Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR must not be mixed with any other insulin or medicinal
products or diluted. Mixing or diluting can change its time/action profile and
mixing can cause precipitation.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Insulin pen</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The ABASAGLAR cartridges are to be used only in conjunction with a
Lilly reusable insulin pen (see section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pen should be used as recommended in the information provided with
the device. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The instructions for using the pen must be followed carefully for
loading the cartridge, attaching the needle, and administering the insulin
injection. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If the insulin pen is damaged or not working properly (due to
mechanical defects) it has to be discarded, and a new insulin pen has to be
used. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Cartridge</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Inspect the cartridge before use. It must only be used if the
solution is clear, colourless, with no solid particles visible, and if it is of
water-like consistency. Since ABASAGLAR is a solution, it does not require
re-suspension before use. Air bubbles must be removed from the cartridge before
injection (see instructions for using the pen).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To prevent the possible transmission of disease, each pen must be
used by one patient only. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Empty cartridges must not be refilled and must be properly
discarded. Insulin label must always be checked before each injection to avoid
medication errors between insulin glargine and other insulins (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><b><span lang=EN-GB>7.  MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The
Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>8.  MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/009</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>9.  DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Date of first authorisation: 9 September 2014</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Date of latest renewal: 25 July 2019</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>10.  DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu <br clear=all
style='page-break-before:always'>
<b>1. NAME OF </b><b>THE MEDICINAL PRODUCT</b></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR</span><span lang=EN-GB> 100&nbsp;units/mL KwikPen solution
for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR</span><span lang=EN-GB> 100&nbsp;units/mL Tempo Pen solution
for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>2. QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>Each mL
contains 100&nbsp;units insulin glargine* (equivalent to 3.64&nbsp;mg). </span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Each pen contains 3&nbsp;mL of solution for injection, equivalent to
300&nbsp;units. </span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>* produced by recombinant DNA technology in <i>Escherichia coli</i>.
</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For the full list of excipients, see section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>3. PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Solution for
injection (injection) </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clear,
colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB style='text-transform:uppercase'>4. </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.1 Therapeutic indications</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Treatment of diabetes mellitus in adults, adolescents and children
aged 2&nbsp;years and above.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.2 Posology
and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR contains insulin glargine, an insulin analogue and has a
prolonged duration of action. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR should be administered once daily at any time but at the
same time each day. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The dose regimen (dose and timing) should be individually adjusted.
In patients with type&nbsp;2 diabetes mellitus, ABASAGLAR can also be given
together with orally active antidiabetic medicinal products. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The potency of this medicinal product is stated in units. These
units are exclusive to insulin glargine and are not the same as IU or the units
used to express the potency of other insulin analogues (see section 5.1). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Elderly population (&#8805;65 years old)</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the elderly, progressive deterioration of renal function may lead
to a steady decrease in insulin requirements.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients with renal impairment, insulin requirements
may be diminished due to reduced insulin metabolism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>In patients with hepatic impairment, insulin
requirements may be diminished due to reduced capacity for gluconeogenesis and
reduced insulin metabolism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Adolescents and children aged 2 years and older</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of insulin glargine have been established in
adolescents and children aged 2&nbsp;years and older (see section 5.1). The
dose regimen (dose and timing) should be individually adjusted.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Children below 2 years of age</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of insulin glargine have not been
established. No data are available. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Switch from other insulins to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>When switching from
a treatment regimen with an intermediate or long-acting insulin to a regimen
with ABASAGLAR, a change of the dose of the basal insulin may be required and
the concomitant antidiabetic treatment may need to be adjusted (dose and timing
of additional regular insulins or fast-acting insulin analogues or the dose of
oral antidiabetic medicinal products). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Switch from twice daily NPH insulin to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To reduce the risk of nocturnal and early morning hypoglycaemia,
patients who are changing their basal insulin regimen from a twice daily NPH
insulin to a once daily regimen with ABASAGLAR should reduce their daily dose
of basal insulin by 20-30&nbsp;% during the first weeks of treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Switch
from insulin glargine 300 units/ml to ABASAGLAR</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR and Toujeo
(insulin glargine 300 units/ml) are not bioequivalent and are not directly
interchangeable. To reduce the risk of hypoglycemia, patients who are changing
their basal insulin regimen from an insulin regimen with once daily insulin
glargine 300 units/ml to a once daily regimen with ABASAGLAR should reduce
their dose by approximately 20%.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>During the first weeks the reduction should, at least partially, be
compensated by an increase in mealtime insulin, after this period the regimen
should be adjusted individually. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Close metabolic monitoring is recommended during the switch and in
the initial weeks thereafter. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>With improved metabolic control and resulting increase in insulin
sensitivity a further adjustment in dose regimen may become necessary. Dose
adjustment may also be required, for example, if the patient's weight or
life-style changes, change of timing of insulin dose or other circumstances
arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see
section 4.4). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients with high insulin doses because of antibodies to human
insulin may experience an improved insulin response with ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is administered subcutaneously.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR should not be administered intravenously. The prolonged
duration of action of insulin glargine is dependent on its injection into
subcutaneous tissue. Intravenous administration of the usual subcutaneous dose
could result in severe hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>There are no clinically relevant differences in serum insulin or
glucose levels after abdominal, deltoid or thigh administration of insulin
glargine. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Injection sites should always be rotated within the same region in
order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see
section 4.4 and 4.8).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR must not be mixed with any other insulin or diluted.
Mixing or diluting can change its time/action profile and mixing can cause
precipitation. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For further details on handling, see section 6.6.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before using ABASAGLAR solution for injection in pre&#8209;filled
pen, the instructions for use included in the package leaflet must be read
carefully (see section 6.6).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><u><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>KwikPen</span></u></i></p>

<p class=Default><i><u><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=Default><a name="_Hlk46321788"><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>The</span></a><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'> </span><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>K</span><span lang=BG style='font-size:
11.0pt;font-family:"Times New Roman",serif'>wik</span><span style='font-size:
11.0pt;font-family:"Times New Roman",serif'>P</span><span lang=BG
style='font-size:11.0pt;font-family:"Times New Roman",serif'>en is </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>registered</span><span
lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'> in two
presentations. One <a name="_Hlk46321308">delivers 1&nbsp;60&nbsp;units</a> in
steps of</span><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>
</span><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>1&nbsp;unit
in a single injection</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>
and the other</span><span lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>
delivers 1&nbsp;&nbsp;</span><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>8</span><span
lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>0&nbsp;units
in steps of 1&nbsp;unit in a single injection. The needed dose is dialled in
units. The number of units is shown in the dose window of the pen</span><span
lang=BG style='font-size:11.0pt;font-family:"Times New Roman",serif'>. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Tempo Pen</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><a name="_Hlk38964026"><span
lang=EN-GB>The Tempo Pen delivers 1&nbsp;&nbsp;80&nbsp;units in steps of 1&nbsp;unit
in a single injection. The needed dose is dialled in units. The number of units
is shown in the dose window of the pen.</span></a></p>

<p class=mdTblEntry style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The Tempo Pen can be used with the optional transfer
module Tempo Smart Button (see section 6.6).</span></p>

<p class=mdTblEntry style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk32916492"><span lang=EN-GB>As with any insulin injection,
when using the Tempo Pen, Smart Button and the mobile application,</span></a><span
lang=EN-GB style='font-family:"Calibri",sans-serif'> </span><span lang=EN-GB>the
patient should be instructed to check their blood sugar levels when considering
or making decisions about another injection if they are unsure how much they
have injected.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3 Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Hypersensitivity to the active substance or to any of
the excipients listed in section 6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.4 Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In order to
improve the traceability of biological medicinal products, the name and the
batch number of the administered medicinal product should be clearly recorded.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Diabetic ketoacidosis</span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is not the insulin of choice for the treatment of diabetic
ketoacidosis. Instead, regular insulin administered intravenously is
recommended in such cases. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Insulin requirements and dose adjustments</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In case of insufficient glucose control or a tendency to
hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the
prescribed treatment regimen, injection sites and proper injection technique
and all other relevant factors must be reviewed before dose adjustment is
considered.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Transferring a patient to another type or brand of insulin should be
done under strict medical supervision. Changes in strength, brand
(manufacturer), type (regular, NPH, lente, long&#8209;acting, etc.), origin
(animal, human, human insulin analogue) and/or method of manufacture may result
in the need for a change in dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Hypoglycaemia</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The time of occurrence of hypoglycaemia depends on the action
profile of the insulins used and may, therefore, change when the treatment
regimen is changed. Due to more sustained basal insulin supply with insulin
glargine, less nocturnal but more early morning hypoglycaemia can be expected.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Particular caution should be exercised, and intensified blood
glucose monitoring is advisable in patients in whom hypoglycaemic episodes
might be of particular clinical relevance, such as in patients with significant
stenoses of the coronary arteries or of the blood vessels supplying the brain
(risk of cardiac or cerebral complications of hypoglycaemia) as well as in
patients with proliferative retinopathy, particularly if not treated with
photocoagulation (risk of transient amaurosis following hypoglycaemia). </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be aware of circumstances where warning symptoms of
hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be
changed, be less pronounced or be absent in certain risk groups. These include
patients:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom glycaemic control
is markedly improved,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom hypoglycaemia
develops gradually,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  who are elderly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  after transfer from
animal insulin to human insulin,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  in whom an autonomic
neuropathy is present,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  with a long history of
diabetes,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  suffering from a
psychiatric illness,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  receiving concurrent
treatment with certain other medicinal products (see section 4.5).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Such situations may result in severe hypoglycaemia (and possibly
loss of consciousness) prior to the patient's awareness of hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The prolonged effect of subcutaneous insulin glargine may delay
recovery from hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If normal or decreased values for glycated haemoglobin are noted,
the possibility of recurrent, unrecognised (especially nocturnal) episodes of
hypoglycaemia must be considered. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Adherence of the patient to the dose and dietary regimen, correct
insulin administration and awareness of hypoglycaemia symptoms are essential to
reduce the risk of hypoglycaemia. Factors increasing the susceptibility to
hypoglycaemia require particularly close monitoring and may necessitate dose
adjustment. These include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  change in the injection
area,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  improved insulin
sensitivity (e.g., by removal of stress factors),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  unaccustomed, increased
or prolonged physical activity,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  intercurrent illness
(e.g. vomiting, diarrhoea),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  inadequate food intake,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  missed meals,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  alcohol consumption,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  certain uncompensated
endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or
adrenocortical insufficiency),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  concomitant treatment
with certain other medicinal products.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Injection
technique</span></u></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients must be instructed to perform
continuous rotation of the injection site to reduce the risk of developing
lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed
insulin absorption and worsened glycaemic control following insulin injections at
sites with these reactions. A sudden change in the injection site to an
unaffected area has been reported to result in hypoglycaemia. Blood glucose
monitoring is recommended after the change in the injection site, and dose
adjustment of antidiabetic medications may be considered.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Intercurrent illness</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Intercurrent illness requires intensified metabolic monitoring. In
many cases urine tests for ketones are indicated, and often it is necessary to
adjust the insulin dose. The insulin requirement is often increased. Patients
with type&nbsp;1 diabetes must continue to consume at least a small amount of
carbohydrates on a regular basis, even if they are able to eat only little or
no food, or are vomiting etc. and they must never omit insulin entirely. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Insulin antibodies</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin administration may cause insulin antibodies to form. In rare
cases, the presence of such insulin antibodies may necessitate adjustment of
the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see
section 5.1).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Medication errors</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medication
errors have been reported in which other insulins, particularly short&#8209;acting
insulins, have been accidentally administered instead of insulin glargine.
Insulin label must always be checked before each injection to avoid medication
errors between ABASAGLAR pre-filled pen as well as other insulins.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Combination of ABASAGLAR with pioglitazone</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Cases of cardiac failure have been reported when pioglitazone was
used in combination with insulin, especially in patients with risk factors for
development of cardiac heart failure. This should be kept in mind if treatment
with the combination of pioglitazone and ABASAGLAR is considered. If the
combination is used, patients should be observed for signs and symptoms of
heart failure, weight gain and oedema. Pioglitazone should be discontinued if
any deterioration in cardiac symptoms occurs.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Tempo Pen</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Tempo Pen
contains a magnet (see section 6.5) that may interfere with the functions of an
implantable electronic medical device, such as a pacemaker. T</span><span
lang=EN-GB>he magnetic field extends to approximately 1.5&nbsp;cm</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Sodium
content</span></u></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product contains less than 1&nbsp;mmol sodium
(23&nbsp;mg) per dose, i.e., essentially sodium&#8209;free.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.5 Interaction with other medicinal products
and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A number of substances affect glucose metabolism and may require
dose adjustment of insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Substances that may enhance the blood-glucose&#8209;lowering effect
and increase susceptibility to hypoglycaemia include oral antidiabetic
medicinal products, angiotensin converting enzyme (ACE) inhibitors,
disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,
pentoxifylline, propoxyphene, salicylates, somatostatin anologues and
sulphonamide antibiotics. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Substances that may reduce the blood-glucose-lowering effect include
corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,
oestrogens, progestogens, phenothiazine derivatives, somatropin,
sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.
clozapine and olanzapine) and protease inhibitors. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Beta-blockers, clonidine, lithium salts or alcohol may either
potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine
may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In addition, under the influence of sympatholytic medicinal products
such as beta-blockers, clonidine, guanethidine and reserpine, the signs of
adrenergic counter-regulation may be reduced or absent.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.6 </span></b><b><span lang=EN-GB>Fertility, p</span></b><b><span
lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For insulin glargine no clinical data on exposed pregnancies from
controlled clinical studies are available. A large amount of data on pregnant
women (more than 1,000&nbsp;pregnancy outcomes) indicate no specific adverse
effects of insulin glargine on pregnancy and no specific malformative nor
feto/neonatal toxicity of insulin glargine. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='background:lime'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal data do not indicate reproductive toxicity. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The use of ABASAGLAR may be considered during pregnancy, if clinically
needed.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is essential for patients with pre-existing or gestational
diabetes to maintain good metabolic control throughout pregnancy to prevent
adverse outcomes associated with hyperglycaemia. Insulin requirements may
decrease during the first trimester and generally increase during the second
and third trimesters. Immediately after delivery, insulin requirements decline
rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose
control is essential. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>It is unknown whether insulin glargine is excreted in human milk. No
metabolic effects of ingested insulin glargine on the breast&#8209;fed
newborn/infant are anticipated since insulin glargine as a peptide is digested
into amino acids in the human gastrointestinal tract. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Breast-feeding women may require adjustments in insulin dose and
diet. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Animal studies do not indicate direct harmful effects with respect
to fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.7 Effects on ability to drive and use
machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The patient's ability to concentrate and react may be impaired as a
result of hypoglycaemia or hyperglycaemia or, for example, as a result of
visual impairment. This may constitute a risk in situations where these
abilities are of special importance (e.g. driving a car or using machines).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be advised to take precautions to avoid
hypoglycaemia whilst driving. This is particularly important in those who have
reduced or absent awareness of the warning symptoms of hypoglycaemia or have
frequent episodes of hypoglycaemia. It should be considered whether it is
advisable to drive or operate machines in these circumstances.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>4.8 Undesirable
effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Summary of safety profile</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hypoglycaemia (very common), in general the most frequent adverse reaction
of insulin therapy, may occur if the insulin dose is too high in relation to
the insulin requirement (see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Tabulated list of adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>The following related adverse reactions from clinical
trials are listed below as MedDRA preferred term by system organ class and in
order of decreasing incidence (very common: &#8805;1/10; common: &#8805;1/100
to &lt;1/10; uncommon: &#8805;1/1,000 to &lt;1/100; rare: &#8805;1/10,000 to
&lt;1/1,000; very rare: &lt;1/10,000 <a name="_Hlk23422201"><span
style='color:black'>and not known (cannot be estimated from the available data</span></a>).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Within each frequency grouping, adverse reactions are presented in
order of decreasing seriousness.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="99%"
 style='margin-left:12.5pt;border-collapse:collapse;border:none'>
 <tr style='height:16.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>MedDRA system organ classes</span></b></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Very common</span></b></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Common</span></b></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Uncommon</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Rare</span></b></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Very rare</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Not known</span></b></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Immune system disorders </span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:16.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Allergic reactions</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:16.75pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Metabolism and nutrition disorders</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Hypoglycaemia</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:16.3pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Nervous system disorders</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.3pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:11.0pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Dysgeusia</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:11.0pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Eyes disorders</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Visual impairment </span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Retinopathy</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Lipohypertrophy</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Lipoatrophy</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Cutaneous amyloidosis</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" style='width:13.0%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" colspan=2 valign=top style='width:22.24%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Myalgia</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" valign=top style='width:12.28%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="87%" colspan=8 valign=top style='width:87.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>General disorders and administration site conditions</span></b></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" valign=top style='width:22.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Injection site reactions</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.42%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:5.75pt'>
  <td width="22%" valign=top style='width:22.1%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal style='margin-bottom:2.55pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>Oedema</span></p>
  </td>
  <td width="15%" colspan=2 valign=top style='width:15.2%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="12%" colspan=2 valign=top style='width:12.42%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="15%" valign=top style='width:15.18%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="11%" valign=top style='width:11.02%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>X</span></p>
  </td>
  <td width="11%" valign=top style='width:11.08%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width="13%" valign=top style='width:13.0%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:5.75pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=155 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=106 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=86 style='border:none'></td>
  <td width=106 style='border:none'></td>
  <td width=77 style='border:none'></td>
  <td width=78 style='border:none'></td>
  <td width=91 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Metabolism and nutrition disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Severe hypoglycaemic attacks, especially if recurrent, may lead to
neurological damage. Prolonged or severe hypoglycaemic episodes may be
life-threatening. In many patients, the signs and symptoms of neuroglycopenia
are preceded by signs of adrenergic counter-regulation. Generally, the greater
and more rapid the decline in blood glucose, the more marked is the phenomenon
of counter-regulation and its symptoms.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Immune system disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Immediate-type allergic reactions to insulin are rare. Such
reactions to insulin (including insulin glargine) or the excipients may, for
example, be associated with generalised skin reactions, angio-oedema,
bronchospasm, hypotension and shock, and may be life-threatening.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Eyes disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A marked change in glycaemic control may cause temporary visual
impairment, due to temporary alteration in the turgidity and refractive index
of the lens.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Long-term improved glycaemic control decreases the risk of progression
of diabetic retinopathy. However, intensification of insulin therapy with
abrupt improvement in glycaemic control may be associated with temporary
worsening of diabetic retinopathy. In patients with proliferative retinopathy,
particularly if not treated with photocoagulation, severe hypoglycaemic
episodes may result in transient amaurosis.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Skin and subcutaneous tissue disorders</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal><span lang=EN-GB>Lipodystrophy and cutaneous amyloidosis may
occur at the injection site and delay local insulin absorption. Continuous
rotation of the injection site within the given injection area may help to
reduce or prevent these reactions (</span><span lang=EN-GB>see section 4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB>General disorders and administration site
conditions</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Injection site reactions include redness, pain, itching,
hives, swelling, or inflammation. Most minor reactions to insulins at the
injection site usually resolve in a few days to a few weeks. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Rarely, insulin may cause sodium retention and oedema particularly
if previously poor metabolic control is improved by intensified insulin therapy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In general, the safety profile for children and adolescents
(&#8804;&nbsp;18&nbsp;years of age) is similar to the safety profile for
adults. The adverse reaction reports received from post marketing surveillance
included relatively more frequent injection site reactions (injection site
pain, injection site reaction) and skin reactions (rash, urticaria) in children
and adolescents (&#8804;&nbsp;18&nbsp;years of age) than in adults. Clinical
study safety data are not available for children under 2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><i><span
lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4.9 Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Symptoms</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin overdose may lead to severe and sometimes long-term and
life-threatening hypoglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Management</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Mild episodes of hypoglycaemia can usually be treated with oral
carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or
physical activity may be needed. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>More severe episodes with coma, seizure, or neurologic impairment
may be treated with intramuscular/subcutaneous glucagon or concentrated
intravenous glucose. Sustained carbohydrate intake and observation may be
necessary because hypoglycaemia may recur after apparent clinical recovery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>5.1  Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: Drugs used in diabetes, insulins and analogues for injection,
long-acting. ATC Code: A10AE04.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR is a
biosimilar medicinal product. Detailed information is available on the website
of the European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Mechanism of
action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
is a human insulin analogue designed to have a low solubility at neutral pH. It
is completely soluble at the acidic pH of the ABASAGLAR injection solution
(pH&nbsp;4). After injection into the subcutaneous tissue, the acidic solution
is neutralised leading to formation of micro-precipitates from which small
amounts of insulin glargine are continuously released, providing a smooth,
peakless, predictable concentration/time profile with a prolonged duration of
action.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
is metabolised into 2 active metabolites M1 and M2 (see section 5.2).</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Insulin
receptor binding</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In vitro</span></i><span
lang=EN-GB> studies indicate that the affinity of insulin glargine and its
metabolites M1 and M2 for the human insulin receptor is similar to the one of
human insulin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>IGF-1 receptor
binding: The affinity of insulin glargine for the human IGF-1 receptor is
approximately 5 to 8-fold greater than that of human insulin (but approximately
70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1
receptor with slightly lower affinity compared to human insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The total therapeutic insulin concentration (insulin glargine and
its metabolites) found in type&nbsp;1 diabetic patients was markedly lower than
what would be required for a half maximal occupation of the IGF-1 receptor and
the subsequent activation of the mitogenic-proliferative pathway initiated by
the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may
activate the mitogenic-proliferative pathway; however, the therapeutic
concentrations found in insulin therapy, including in ABASAGLAR therapy, are
considerably lower than the pharmacological concentrations required to activate
the IGF-1 pathway. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary
activity of insulin, including insulin glargine, is regulation of glucose
metabolism. Insulin and its analogues lower blood glucose levels by stimulating
peripheral glucose uptake, especially by skeletal muscle and fat, and by
inhibiting hepatic glucose production. Insulin inhibits lipolysis in the
adipocyte, inhibits proteolysis and enhances protein synthesis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
pharmacology studies, intravenous insulin glargine and human insulin have been
shown to be equipotent when given at the same doses. As with all insulins, the
time course of action of insulin glargine may be affected by physical activity
and other variables.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In euglycaemic
clamp studies in healthy subjects or in patients with type&nbsp;1 diabetes, the
onset of action of subcutaneous insulin glargine was slower than with human NPH
insulin, its effect profile was smooth and peakless, and the duration of its
effect was prolonged.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
graph shows the results from a study in patients:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Figure 1: </span></b><b>Activity profile in patients with type</b><span
lang=EN-GB>&nbsp;</span><b>1 diabetes</b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=right style='text-align:right;line-height:normal;
page-break-after:avoid'><span style='position:absolute;z-index:251686912;
left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px'><img
width=652 height=274 src="ABASAGLAR_clean_files/image005.png"></span><span
style='position:absolute;z-index:251684864;left:0px;margin-left:161px;
margin-top:233px;width:159px;height:39px'><img width=159 height=39
src="ABASAGLAR_clean_files/image006.png" alt="Time (h) after s.c injection"></span><span
lang=EN-GB><img border=0 width=590 height=286 id="Picture 2"
src="ABASAGLAR_clean_files/image007.jpg"></span></p>

<p class=MsoNormal><span lang=EN-GB style='display:none'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>* Determined as
amount of glucose infused to maintain constant plasma glucose levels (hourly
mean values)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The longer
duration of action of subcutaneous insulin glargine is directly related to its
slower rate of absorption and supports once daily administration. The time
course of action of insulin and insulin analogues such as insulin glargine may
vary considerably in different individuals or within the same individual</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a clinical
study, symptoms of hypoglycaemia or counter-regulatory hormone responses were
similar after intravenous insulin glargine and human insulin both in healthy
volunteers and patients with type&nbsp;1 diabetes.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Clinical safety and efficacy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In clinical
studies, antibodies that cross-react with human insulin and insulin glargine
were observed with the same frequency in both NPH-insulin and insulin glargine
treatment groups.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Effects of
insulin glargine (once daily) on diabetic retinopathy were evaluated in an
open-label 5&nbsp;year NPH-controlled study (NPH given bid) in 1024 type&nbsp;2
diabetic patients in which progression of retinopathy by 3 or more steps on the
Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by
fundus photography. No significant difference was seen in the progression of
diabetic retinopathy when insulin glargine was compared to NPH insulin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The ORIGIN
(Outcome Reduction with Initial Glargine INtervention) study was a multicenter,
randomised, 2x2 factorial design study conducted in 12,537 participants at high
cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired
glucose tolerance (IGT) (12% of participants) or type&nbsp;2 diabetes mellitus
treated with &#8804;1 antidiabetic oral agent (88% of participants).
Participants were randomised (1:1) to receive insulin glargine (n=6,264),
titrated to reach FPG &#8804;95 mg/dL (5.3 mM), or standard care (n=6,273).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The first
co-primary efficacy outcome was the time to the first occurrence of CV death,
nonfatal myocardial infarction (MI), or nonfatal stroke, and the second
co-primary efficacy outcome was the time to the first occurrence of any of the
first co-primary events, or revascularisation procedure (coronary, carotid, or
peripheral), or hospitalisation for heart failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Secondary
endpoints included all-cause mortality and a composite microvascular outcome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Insulin glargine
did not alter the relative risk for CV disease and CV mortality when compared
to standard of care. There were no differences between insulin glargine and
standard care for the two co-primary outcomes; for any component endpoint
comprising these outcomes; for all-cause mortality; or for the composite
microvascular outcome.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Mean dose of
insulin glargine by study end was 0.42 U/kg. At baseline, participants had a
median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9
to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care
group throughout the duration of follow-up. The rates of severe hypoglycaemia
(affected participants per 100 participant years of exposure) were 1.05 for
insulin glargine and 0.30 for standard care group and the rates of confirmed
non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard
care group. Over the course of this 6-year study, 42% of the insulin glargine
group did not experience any hypoglycaemia. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>At the last
on-treatment visit, there was a mean increase in body weight from baseline of
1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the
standard care group.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Paediatric
population</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a randomised,
controlled clinical study, paediatric patients (age range 6 to 15&nbsp;years)
with type&nbsp;1 diabetes (n=349) were treated for 28&nbsp;weeks with a basal-bolus
insulin regimen where regular human insulin was used before each meal. Insulin
glargine was administered once daily at bedtime and NPH human insulin was
administered once or twice daily. Similar effects on glycohaemoglobin and the
incidence of symptomatic hypoglycaemia were observed in both treatment groups,
however fasting plasma glucose decreased more from baseline in the insulin
glargine group than in the NPH group. There was less severe hypoglycaemia in
the insulin glargine group as well. One hundred forty three of the patients
treated with insulin glargine in this study continued treatment with insulin
glargine in an uncontrolled extension study with mean duration of follow-up of
2&nbsp;years. No new safety signals were seen during this extended treatment
with insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A crossover
study comparing insulin glargine plus lispro insulin to NPH plus regular human
insulin (each treatment administered for 16 weeks in random order) in 26
adolescent type&nbsp;1 diabetic patients aged 12 to 18&nbsp;years was also
performed. As in the paediatric study described above, fasting plasma glucose
reduction from baseline was greater in the insulin glargine group than in the
NPH group. HbA<sub>1c</sub> changes from baseline were similar between
treatment groups; however blood glucose values recorded overnight were
significantly higher in the insulin glargine/ lispro group than the NPH/regular
group, with a mean nadir of 5.4&nbsp;mM vs. 4.1&nbsp;mM. Correspondingly, the
incidences of nocturnal hypoglycaemia were 32&nbsp;% in the insulin glargine /
lispro group vs. 52&nbsp;% in the NPH / regular group.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A 24-week
parallel group study was conducted in 125 children with type&nbsp;1 diabetes
mellitus aged 2 to 6&nbsp;years, comparing insulin glargine given once daily in
the morning to NPH insulin given once or twice daily as basal insulin. Both
groups received bolus insulin before meals. The primary aim of demonstrating
non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and
there was a trend to an increase of hypoglycaemic events with insulin glargine
[insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].
Glycohaemoglobin and glucose variabilities were comparable in both treatment
groups. No new safety signals were observed in this trial.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.2 Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In healthy subjects and diabetic patients, insulin serum
concentrations indicated a slower and much more prolonged absorption and showed
a lack of a peak after subcutaneous injection of insulin glargine in comparison
to human NPH insulin. Concentrations were thus consistent with the time profile
of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the
activity profiles over time of insulin glargine and NPH insulin. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin glargine injected once daily will reach steady state levels
in 2-4 days after the first dose. </span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>After subcutaneous injection in diabetic patients, insulin glargine
is rapidly metabolised at the carboxyl terminus of the Beta chain with
formation of two active metabolites M1 (21A-Gly-insulin) and M2
(21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is
the metabolite M1. The exposure to M1 increases with the administered dose of
insulin glargine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pharmacokinetic and pharmacodynamic findings indicate that the effect
of the subcutaneous injection with insulin glargine is principally based on
exposure to M1. Insulin glargine and the metabolite M2 were not detectable in
the vast majority of subjects and, when they were detectable their
concentration was independent of the administered dose of insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>When given intravenously the elimination half-life of insulin
glargine and human insulin were comparable. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'>&nbsp;</p>

<p style='margin:0in'><u><span lang=EN-GB style='font-size:11.0pt'>Special
populations</span></u></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>In clinical
studies, subgroup analyses based on age and gender did not indicate any
difference in safety and efficacy in insulin glargine-treated patients compared
to the entire study population.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB>Paediatric population</span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pharmacokinetics in children aged 2 to less than 6 years with
type&nbsp;1 diabetes mellitus was assessed in one clinical study (see section
5.1). Plasma trough levels of insulin glargine and its main M1 and M2
metabolites were measured in children treated with insulin glargine, revealing
plasma concentration patterns similar to adults, and providing no evidence for
accumulation of insulin glargine or its metabolites with chronic dosing.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5.3 Preclinical safety data</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Non-clinical data reveal no special hazard for humans based on
conventional studies of safety pharmacology, repeated dose toxicity,
genotoxicity, carcinogenic potential, toxicity to reproduction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>6. PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.1  List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Zinc oxide</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Metacresol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Glycerol</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Hydrochloric acid (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Sodium hydroxide (for pH adjustment)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Water for injections</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.2  Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This medicinal product must not be mixed with other medicinal
products. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.3  Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt'>2 years.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Shelf life after first use </span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The medicinal product may be stored for a maximum of 28&nbsp;days up
to 30C and away from direct heat or direct light. Pens in use must not be
stored in the refrigerator. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pen cap must be put back on the pen after each injection in
order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.4  Special precautions for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Before use</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2C - 8C).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not store ABASAGLAR next to the freezer compartment or a freezer
pack.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep the pre-filled pen in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>In use </span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>For storage conditions after first opening of this medicinal
product, see section 6.3.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>6.5  Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>KwikPen</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>3 mL solution in a cartridge (type&nbsp;1 colourless glass) with a
plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and
halobutyl rubber) with aluminium seal. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The cartridge is sealed in a disposable pen injector. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Packs of 5&nbsp;pre-filled
pens and multipacks containing 10 (2 packs of 5) pre-filled pens. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Tempo Pen</span></u></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>3 mL solution in a cartridge (type&nbsp;1 colourless glass) with a
plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and
halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable
pen injector. The Tempo Pen contains a magnet (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Packs of 5&nbsp;<a name="_Hlk44087754">pre-filled pens</a> and
multipacks containing 10 (2 packs of 5) pre-filled pens</span><span lang=EN-GB>.</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Needles are not
included in the pack.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>6.6  Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR must not be mixed with any other insulin or medicinal
products or diluted. Mixing or diluting can change its time/action profile and
mixing can cause precipitation.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Inspect the cartridge before use. It must only be used if the
solution is clear, colourless, with no solid particles visible, and if it is of
water-like consistency. Since ABASAGLAR is a solution, it does not require
re-suspension before use. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR must not be mixed with any other insulin or diluted.
Mixing or diluting can change its time/action profile and mixing can cause
precipitation.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Empty pens must never be reused and must be properly discarded. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To prevent the possible transmission of disease, each pen must be
used by one patient only. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin label must always be checked before each injection to avoid
medication errors between insulin glargine and other insulins (see section
4.4).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The patient should be advised to read the instructions for use
included in the package leaflet carefully before using ABASAGLAR solution for
injection in pre&#8209;filled pen.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><a name="_Hlk20390276"><u><span lang=EN-GB>Tempo Pen</span></u></a></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=mdTblEntry style='line-height:normal'><a name="_Hlk38978858"></a><a
name="_Hlk45820494"><span lang=EN-GB style='font-size:11.0pt'>The Tempo Pen is
designed to work with the Tempo Smart Button. </span></a><span lang=EN-GB
style='font-size:11.0pt'>The Tempo Smart Button is an optional product that can
be attached to the Tempo Pen dose knob and aids in transmitting Abasaglar dose
information from the Tempo Pen to a compatible mobile application. The Tempo
Pen injects insulin with or without the Tempo Smart Button attached. To
transmit data to the mobile application, follow the instructions provided with
the Tempo Smart Button and the instructions with the mobile application. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>7.  MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The
Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>8.  MARKETING AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/007</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES-TRAD>EU/1/14/944/008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES-TRAD>EU/1/14/944/012</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES-TRAD>EU/1/14/944/013</span></p>

<p class=MsoNormal><span lang=ES-TRAD style='color:black'>EU/1/14/944/014</span></p>

<p class=MsoNormal><span lang=ES style='color:black'>EU/1/14/944/015</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=ES>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>9.  DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Date of first authorisation: 9 September 2014</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Date of latest renewal: 25 July 2019</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>10.  DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Detailed information on this medicinal product is available on the
website of the European Medicines Agency </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:6.0pt;
margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;
line-height:normal;page-break-after:avoid;text-autospace:none'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
0in;margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>A. MANUFACTURER(S) OF THE
BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE </span></b></p>

<p class=MsoNormal style='margin-top:14.0pt;margin-right:6.0pt;margin-bottom:
11.0pt;margin-left:42.35pt;text-indent:-.5in;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND
USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>C. OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:
avoid;text-autospace:none'><b><span lang=EN-GB>D. CONDITIONS OR RESTRICTIONS
WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TittleB><span lang=EN-GB style='color:windowtext'>A. MANUFACTURER(S)
OF THE BIOLOGICAL ACTIVE SUBSTANCE(S)  AND MANUFACTURER(S) RESPONSIBLE FOR
BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Name and address of the manufacturers of the biological
active substance</span></u><span lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:"Verdana",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Lilly del Caribe, Inc.<br>
12.3 km 65th Infantry Road<br>
Carolina, PR 00985<br>
Puerto Rico</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Eli Lilly and Company</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Indianapolis </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Indiana 46285 </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>USA</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><u><span lang=EN-GB>Name and address of the manufacturer responsible for
batch release</span></u></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:7.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>ABASAGLAR</span><span lang=EN-GB> 100&nbsp;units/mL
solution for injection in a cartridge and pre-filled pen</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Lilly France S.A.S.<br>
2, rue du Colonel Lilly<br>
F-67640 Fegersheim<br>
France</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:7.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>ABASAGLAR</span><span lang=EN-GB> 100&nbsp;units/mL
solution for injection in a cartridge</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:7.1pt'><span lang=IT>Eli Lilly Italia
S.p.A., </span></p>

<p class=MsoNormal style='margin-left:7.1pt'><span lang=IT>Via Gramsci 731-733,
</span></p>

<p class=MsoNormal style='margin-left:7.1pt'><span lang=IT>50019 Sesto
Fiorentino, (FI) </span></p>

<p class=MsoNormal style='margin-left:7.1pt'><span lang=IT>Italy.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=TittleB><span lang=EN-GB style='color:windowtext'>B. CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>Medicinal product subject to medical prescription </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=TittleB><span lang=EN-GB style='color:windowtext'>C. OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The </span><span lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>requirements
for submission of</span><span lang=EN-GB> PSURs for this </span><span
lang=EN-GB style='font-family:"TimesNewRomanPSMT",serif'>medicinal product are</span><span
lang=EN-GB> set out in the list of Union reference dates (EURD list) provided
for under Article 107c(7) of Directive 2001/83/EC and </span><span lang=EN-GB
style='font-family:"TimesNewRomanPSMT",serif'>any subsequent updates</span><span
lang=EN-GB> published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=TittleB><span lang=EN-GB style='color:windowtext'>D. CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk management plan (RMP)</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The marketing authorisation holder (MAH) shall perform
the required pharmacovigilance activities and interventions detailed in the
agreed RMP presented in Module 1.8.2 of the marketing authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-left:41.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:41.4pt;text-indent:-.25in;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached. </span></p>

<p class=MsoNormal style='margin-right:5.95pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.95pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON  Cartridge. Pack of 5 and 10</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR 100&nbsp;units/mL
solution for injection in a cartridge</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections. </span><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5 cartridges of
3&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>10 cartridges of 3&nbsp;mL</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>These cartridges are
for use with a Lilly 3&nbsp;mL pen only.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard 28&nbsp;days
after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>EU/1/14/944/003</span><span
lang=FR> <span style='background:lightgrey'>5 cartridges</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR style='background:
lightgrey'>EU/1/14/944/009 10 cartridges</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=FR>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>NN</span></p>

<span lang=X-NONE style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTRIDGE LABEL </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Read the package leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>3&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON  KwikPen. Pack of 5</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR 100&nbsp;units/mL
KwikPen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections.</span><span lang=EN-GB style='background:lightgrey'> See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5 pens of
3&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen 28&nbsp;days
after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>EU/1/14/944/007</span><span
lang=FR> <span style='background:lightgrey'>5 pens</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV style='background:
lightgrey'>EU/1/14/944/012</span><span lang=FR style='background:lightgrey'> 5
pens</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=SV>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=SV>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=FR>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=FR>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON for multipack (with blue box)  KwikPen</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR 100&nbsp;units/mL
KwikPen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections. </span><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Multipack: 10 (2
packs of 5) pens of 3&nbsp;mL. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen
28&nbsp;days after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>EU/1/14/944/008</span><span
lang=FR style='background:lightgrey'> 10 (2 x 5) pens</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=SV style='background:
lightgrey'>EU/1/14/944/013</span><span lang=FR style='background:lightgrey'> 10
(2 x 5) pens</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=SV>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=SV>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON of a multipack (without blue box) - KwikPen</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL KwikPen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections. </span><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>5 pens of 3&nbsp;mL.
Component of a multipack, cant be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen 28&nbsp;days
after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><a name="_Hlk47359922"><span lang=EN-GB>30&nbsp;C</span></a><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=SV>EU/1/14/944/008  </span><span
lang=FR style='background:lightgrey'>10 (2 x 5) </span><span lang=SV
style='background:lightgrey'>pens</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR style='background:
lightgrey'>EU/1/14/944/013  10 (2 x 5) pens</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=SV>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=SV>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=FR>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>LABEL TEXT </span></b><b><span lang=EN-GB>KwikPen</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL </span><span lang=EN-GB>KwikPen injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Read the package leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>3&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON __ Tempo Pen. Pack of 5</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL Tempo Pen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections. </span><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>5&nbsp;pens of
3&nbsp;mL.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen
28&nbsp;days after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/014</span> <span
style='background:lightgrey'>5&nbsp;pens</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN
READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>NN</span><span
lang=EN-GB><br clear=all style='page-break-before:always'>
</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>OUTER CARTON for multipack (with blue box)  Tempo Pen</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL Tempo Pen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for
injections. </span><span lang=EN-GB style='background:lightgrey'>See leaflet
for further information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection. </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Multipack: 10 (2
packs of 5) pens of 3&nbsp;mL. </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen
28&nbsp;days after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/015</span><span
style='background:lightgrey'> </span><span lang=FR style='background:
lightgrey'>10 (2 x 5)</span><span style='background:lightgrey'>&nbsp;pens</span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>2D barcode carrying the unique identifier
included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;border:
none;padding:0in'><b><span lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN READABLE
DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>SN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=X-NONE>NN</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black;background:#CCCCCC'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>INTERMEDIATE CARTON of a multipack (without blue box)  Tempo Pen</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>1. NAME OF THE
MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL Tempo Pen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>2. STATEMENT OF
ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each mL contains
100&nbsp;units insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>3. LIST OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Excipients: zinc
oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for injections.
</span><span lang=EN-GB style='background:lightgrey'>See leaflet for further
information</span><span lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>4. PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB style='background:
lightgrey'>Solution for injection.</span><span lang=EN-GB> </span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>5&nbsp;pens of
3&nbsp;mL. Component of a multipack, cant be sold separately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>5. METHOD AND
ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none'><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>6. SPECIAL WARNING
THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><b><span lang=EN-GB>8. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Discard pen
28&nbsp;days after first use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9. SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Before use:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in original package in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In use: </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store below </span><span lang=EN-GB>30&nbsp;C</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not refrigerate or freeze.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Recap the pen after use to protect from light.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL
PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF
APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=SV>Eli Lilly Nederland B.V. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Papendorpseweg 83, 3528 BJ Utrecht </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The Netherlands</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>12. MARKETING AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/14/944/015  <span
style='background:lightgrey'>10 (2 x 5)&nbsp;pens</span></span></p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<p class=MsoNormal style='line-height:normal'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>13. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>14. GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>15. INSTRUCTIONS ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>16. INFORMATION IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17. UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>LABEL TEXT </span></b><b><span lang=EN-GB>Tempo Pen</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF
ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR
100&nbsp;units/mL Tempo Pen injection</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SC use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>2. METHOD OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:lightgrey'>Read the package leaflet before use</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>3. EXPIRY DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>4. BATCH NUMBER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>3&nbsp;mL</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>6. OTHER</span></b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:5.65pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ABASAGLAR 100&nbsp;units/mL solution for injection</span></b><span
lang=EN-GB> <b>in a cartridge</b></span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start using this medicine
because it contains important information for you. The instructions for using
the insulin pen are provided with your insulin pen. Refer to them before using
your medicine.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your doctor,
pharmacist or nurse.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.</span><span lang=EN-GB> This includes any possible
side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3. How to use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4. Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR contains insulin glargine. This is a modified insulin,
very similar to human insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is used to treat diabetes mellitus in adults, adolescents
and children aged 2&nbsp;years and above.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Diabetes mellitus is a disease where your body does not produce
enough insulin to control the level of blood sugar. Insulin glargine has a long
and steady blood-sugar-lowering action.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are allergic to insulin glargine or any of the other
ingredients of this medicine (listed in section 6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before using ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Follow closely the instructions for posology, monitoring (blood and
urine tests), diet and physical activity (physical work and exercise) as
discussed with your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If your blood sugar is too low (hypoglycaemia), follow the guidance
for hypoglycaemia (see box at the end of this leaflet).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin changes at the injection site</span></i><u><span
lang=EN-GB>.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The injection site should be rotated to
prevent skin changes such as lumps under the skin. The insulin may not work
well if you inject into a lumpy area (See How to use Abasaglar). Contact your
doctor if you are currently injecting into a lumpy area before you start
injecting into a different area. Your doctor may tell you to check your blood
sugar more closely, and to adjust your insulin or your other antidiabetic
medications dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Travel</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before travelling consult your doctor. You may need to talk about:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the availability of your
insulin in the country you are visiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  supplies of insulin etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  correct storage of your
insulin while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  timing of meals and
insulin administration while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the possible effects of
changing to different time zones,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  possible new health risks
in the countries to be visited,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  what you should do in
emergency situations when you feel unwell or become ill.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Illnesses and injuries</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the following situations, the management of your diabetes may
require a lot of care (for example, adjustment to insulin dose, blood and urine
tests):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are ill or have a
major injury then your blood sugar level may increase (hyperglycaemia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are not eating
enough your blood sugar level may become too low (hypoglycaemia).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In most cases you will need a doctor. <b>Make sure that you contact
a doctor early.</b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have type&nbsp;1 diabetes (insulin dependent diabetes
mellitus), do not stop your insulin and continue to get enough carbohydrates.
Always tell people who are caring for you or treating you that you require
insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin treatment can cause the body to produce antibodies to
insulin (substances that act against insulin). However, only very rarely, this
will require a change to your insulin dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Some patients with long-standing type&nbsp;2 diabetes mellitus and
heart disease or previous stroke who were treated with pioglitazone and insulin
experienced the development of heart failure. Inform your doctor as soon as
possible if you experience signs of heart failure such as unusual shortness of
breath or rapid increase in weight or localised swelling (oedema).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Insulin mix-ups</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You must always check </span><span lang=EN-GB>the pack and </span><span
lang=EN-GB>the insulin label before each injection to avoid mix-ups between
ABASAGLAR and other insulins.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is no experience with the use of ABASAGLAR in children below
the age of 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Some medicines cause changes in the blood sugar level (decrease,
increase or both depending on the situation). In each case, it may be necessary
to adjust your insulin dose to avoid blood sugar levels that are either too low
or too high. Be careful when you start or stop taking another medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines. Before taking a medicine ask your
doctor if it can affect your blood sugar level and what action, if any, you
need to take.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Medicines that may cause your blood sugar level to fall
(hypoglycaemia) include:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  all other medicines to
treat diabetes,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  angiotensin converting
enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood
pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  disopyramide (used to
treat certain heart conditions),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  fluoxetine (used to treat
depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  fibrates (used to lower
high levels of blood lipids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  monoamine oxidase (MAO)
inhibitors (used to treat depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  pentoxifylline,
propoxyphene, salicylates (such as aspirin, used to relieve pain and lower
fever), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  somatostatin analogues
(such as octreotide, used to treat an uncommon condition in which you make too
much growth hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  sulphonamide
antibiotics.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Medicines that may cause your blood sugar level to
rise (hyperglycaemia) include:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB>-  corticosteroids
(such as &quot;cortisone&quot; used to treat inflammation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB>-  danazol
(medicine acting on ovulation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  diazoxide (used to treat
high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  diuretics (used to treat
high blood pressure or excessive fluid retention),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  glucagon (pancreas
hormone used to treat severe hypoglycaemia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  isoniazid (used to treat
tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  oestrogens and
progestogens (such as in the contraceptive pill used for birth control), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  phenothiazine derivatives
(used to treat psychiatric disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  somatropin (growth
hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  sympathomimetic medicines
(such as epinephrine [adrenaline], salbutamol, terbutaline used to treat
asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  thyroid hormones (used to
treat thyroid gland disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  atypical antipsychotic
medicines (such as clozapine, olanzapine),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  protease inhibitors (used
to treat HIV).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Your blood sugar level may either rise or fall if you take:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  beta-blockers (used to
treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  clonidine (used to treat
high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  lithium salts (used to
treat psychiatric disorders).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pentamidine (used to treat some infections caused by parasites) may
cause hypoglycaemia which may sometimes be followed by hyperglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Beta-blockers like other sympatholytic medicines (such as clonidine,
guanethidine, and reserpine) may weaken or suppress entirely the first warning
symptoms which help you to recognise a hypoglycaemia. </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are not sure whether you are taking one of those medicines
ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>ABASAGLAR with alcohol</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your blood sugar levels may either rise or fall if you drink
alcohol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ask your doctor or pharmacist for advice before taking any medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Inform your doctor if you are planning to become pregnant, or if you
are already pregnant. Your insulin dose may need to be changed during pregnancy
and after giving birth. Particularly careful control of your diabetes, and
prevention of hypoglycaemia, is important for the health of your baby.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding consult your doctor as you may require
adjustments in your insulin doses and your diet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your ability to concentrate or react may be reduced if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hypoglycaemia
(low blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hyperglycaemia
(high blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have problems with
your sight.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this possible problem in mind in all situations where you might
put yourself and others at risk (such as driving a car or using machines). You
should contact your doctor for advice on driving if:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  you have frequent episodes of hypoglycaemia,</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  the first warning symptoms which help you to recognise
hypoglycaemia are reduced or absent.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>ABASAGLAR contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>This medicine contains less than 1&nbsp;mmol (23&nbsp;mg)
sodium per dose, which means it is essentially sodium-free.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3. How to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Although ABASAGLAR contains the same active substance as Toujeo
(insulin glargine 300&nbsp;units/mL), these medicines are not interchangeable.
The switch from one insulin therapy to another requires medical prescription,
medical supervision and blood glucose monitoring. Please consult your doctor
for further information.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Dose</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Based on your life-style and the results of your blood sugar
(glucose) tests and your previous insulin usage, your doctor will:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  determine how much ABASAGLAR
per day you will need and at what time,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when to check
your blood sugar level, and whether you need to carry out urine tests,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when you may
need to inject a higher or lower dose of ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is a long-acting insulin. Your doctor may tell you to use
it in combination with a short-acting insulin or with tablets used to treat
high blood sugar levels.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Many factors may influence your blood sugar level. You should know
these factors so that you are able to react correctly to changes in your blood
sugar level and to prevent it from becoming too high or too low. See the box at
the end of this leaflet for further information.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR can be used in adolescents and children aged 2&nbsp;years
and above. Use this medicine exactly as your doctor has told you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Frequency of administration</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You need one injection of ABASAGLAR every day, at the same time of
the day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a
vein, since this will change its action and may cause hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your doctor will show you in which area of the skin you should
inject ABASAGLAR. With each injection, change the puncture site within the
particular area of skin that you are using.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>How to handle the cartridges</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The ABASAGLAR cartridges are to be used only in Lilly insulin pens
to ensure you get the correct dose. Not all of these pens may be marketed in
your country.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The pen should be used as recommended in the information provided.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The instructions for using the pen must be followed carefully for
loading the cartridge, attaching the needle, and administering the insulin
injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To prevent the possible transmission of disease, each pen must be
used by one patient only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Look at the cartridge before you use it. Only use it if the solution
is clear, colourless and water-like, and has no visible particles in it. Do not
shake or mix it before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use a new cartridge if you notice that your blood sugar
control is unexpectedly getting worse. This is because the insulin may have
lost some of its effectiveness. If you think you may have a problem with ABASAGLAR,
have it checked by your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Special care before injection</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before injection remove any air bubbles (see instructions for using
the pen).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Make sure that neither alcohol nor other disinfectants or other
substances contaminate the insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not re-fill and re-use empty cartridges. Do not add any other
insulin to the cartridge. Do not mix ABASAGLAR with any other insulins or
medicines. Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Problems with the insulin pen?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Refer to the instructions for using the pen.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><u><span
lang=EN-GB>If the insulin pen is damaged or not working properly (due to
mechanical defects) it has to be discarded, and a new insulin pen has to be used.</span></u></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you use more ABASAGLAR than you should</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you <b>have injected
too much ABASAGLAR</b></span><span lang=EN-GB> or are unsure how much you have
injected</span><span lang=EN-GB>, your blood sugar level may become too low
(hypoglycaemia). Check your blood sugar frequently. In general, to prevent
hypoglycaemia you must eat more food and monitor your blood sugar. For
information on the treatment of hypoglycaemia, see box at the end of this
leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you forget to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you have missed a dose
of ABASAGLAR or if you have not injected enough insulin </span><span
lang=EN-GB>or are unsure how much you have injected</span><span lang=EN-GB>,
your blood sugar level may become too high (hyperglycaemia). Check your blood
sugar frequently. For information on the treatment of hyperglycaemia, see box
at the end of this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.55pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>After injecting</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are unsure how much you have injected then check your blood
sugar levels before deciding if you need another injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you stop using ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This could lead to severe hyperglycaemia (very high blood sugar) and
ketoacidosis (build-up of acid in the blood because the body is breaking down
fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who
will tell you what needs to be done.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>If you notice signs of your blood sugar being too low
(hypoglycaemia), </span></b><span lang=EN-GB>take<b> </b>the<b> </b>action to
increase your blood sugar levels <b>immediately</b></span><span lang=EN-GB>. Hypoglycaemia
(low blood sugar) can be very serious and is very common with insulin treatment
(may affect more than 1 in 10 people). Low blood sugar means that there is not
enough sugar in your blood. If your blood sugar level falls too low, you may
pass out (become unconscious). Serious hypoglycaemia may cause brain damage and
may be life-threatening. For more information, see the box at the end of this
leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Severe allergic reactions </span></b><span lang=EN-GB>(rare, may
affect up to 1 in 1,000 people)  the signs </span><span lang=EN-GB>may include
large-scale skin reactions (rash and itching all over the body), severe
swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall
in blood pressure with rapid heartbeat and sweating. Severe allergic reactions
to insulins may become life-threatening. Tell a doctor straight away if you
notice signs of severe allergic reaction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Skin changes at the injection site</span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none'><span
lang=EN-GB>If you inject insulin too often at the same place, the fatty tissue may
shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy,
may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up
of a protein called amyloid (cutaneous amyloidosis, how often they occur is not
known). The insulin may not work very well if you inject into a lumpy area. Change
the injection site with each injection to help prevent these skin changes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Common side effects </span></b><span lang=EN-GB>(may affect up to 1
in 10 people)</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Skin and allergic reactions at the injection
site</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB>The signs may include reddening,
unusually intense pain when injecting, itching, hives, swelling or
inflammation. They can spread around the injection site. Most minor reactions
to insulins usually disappear in a few days to a few weeks.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare side effects </span></b><span lang=EN-GB>(may affect up to 1 in
1,000 people)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Eye reactions</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A marked change (improvement or worsening) in your blood sugar
control can disturb your vision temporarily. If you have proliferative
retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks
may cause temporary loss of vision.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>General disorders</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In rare cases, insulin treatment may also cause temporary build-up
of water in the body, with swelling in the calves and ankles.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare side-effects </span></b><span lang=EN-GB>(may affect up
to1 in 10,000 people)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In very rare cases, dysgeusia (taste disorders) and myalgia
(muscular pain) can occur.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>In general, the side effects in children and adolescents of 18 years
of age or less are similar to those seen in adults.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Complaints of injection site reactions (injection site pain,
injection site reaction) and skin reactions (rash, urticaria) are reported
relatively more frequently in children and adolescents of 18 years of age or
less than in adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in</span> </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. How to store ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and on the label of the cartridge after EXP. The expiry date
refers to the last day of that month.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Unopened cartridges</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2C - 8C). Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not put ABASAGLAR next to the freezer compartment or a freezer
pack. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep the cartridge in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>In-use cartridges</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Cartridges in use (in the insulin pen) or carried as a spare may be
stored for a maximum of 28&nbsp;days up to 30C and away from direct heat or
direct light. The cartridge in use must not be stored in a refrigerator. Do not
use it after this time period.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR
if the solution is clear, colourless and water like.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The active substance is
insulin glargine. Each millilitre of the solution contains 100&nbsp;units of
the active substance insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The other ingredients
are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 ABASAGLAR
contains sodium), hydrochloric acid and water for injections.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR 100&nbsp;units/mL solution for injection in a cartridge is
a clear and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR comes in a special cartridge to be used only in a Lilly
insulin pen. Each cartridge contains 3&nbsp;mL of solution for injection
(equivalent to 300&nbsp;units) and they are available in packs of 5 and 10
cartridges.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The
Netherlands.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim,
France.</span></p>

<p class=MsoNormal><span lang=PT style='background:lightgrey'>Eli Lilly Italia
S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=PT>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR>Eli Lilly Benelux S.A./N.V.</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;page-break-after:
  avoid'><span lang=NL>Tl/Tel: + 32-(0)2 548 84 84</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><b><span lang=SV>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal;
  page-break-after:avoid'><span lang=SV>Eli Lilly </span><span lang=BG
  style='color:black'>Lietuva</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=LT>Tel. +370 (5) 2649600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=BG>&#1058;&#1055; &quot;&#1045;&#1083;&#1080;
  &#1051;&#1080;&#1083;&#1080;
  &#1053;&#1077;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&quot;
  &#1041;.&#1042;. - &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=BG>&#1090;&#1077;&#1083;. +359 2 491 41 40</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eli Lilly Benelux S.A./N.V.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>Tl/Tel: + 32-(0)2 548 84 84</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=SV>&#268;esk republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=CS>ELI LILLY &#268;R, s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>Tel: + 420 234 664 111</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Magyarorszg</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>Lilly Hungria Kft.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tel: + 36 1 328 5100</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eli Lilly Danmark A/S </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tlf: +45 45 26 60 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=FR>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ES>Charles de Giorgio Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>Tel: + 356 25600 500</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DE>Lilly Deutschland GmbH</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DE>Tel. + 49-(0) 6172 273 2222</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DA>Eli Lilly Nederland B.V. </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>Tel: + 31-(0) 30 60 25 800</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=SV>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>Eli Lilly Nederland B.V.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ET>Tel</span><span lang=ET>: </span><span lang=EN-GB>+372 6 817 280</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NO-NYN>Eli Lilly Norge A.S. </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NO-NYN>Tlf: + 47 22 88 18 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EL style='layout-grid-mode:line'>&#934;&#913;&#929;&#924;&#913;&#931;&#917;&#929;&#914;-&#923;&#921;&#923;&#923;&#933;
  &#913;.&#917;.&#914;.&#917;. </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EL style='layout-grid-mode:line'>&#932;&#951;&#955;: +30 210 629 4600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=SV>sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ET>Eli Lilly Ges.m.b.H. </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ET>Tel: + 43-(0) 1 711 780</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=ES-TRAD>Espaa</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ES>Lilly S.A.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=ES>Tel: + 34-91 663 50 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>Eli Lilly Polska Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=PL>Tel: </span><span lang=EN-GB>+48 22 440 33 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR>Lilly France SAS</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FR>Tl: +33-(0) 1 55 49 34 34</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=FR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=PT>Lilly Portugal Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=NL>Tel: + 351-21-4126600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=DA style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DA>Eli Lilly Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tel: +385 1 2350 999</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Romnia</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=RO>Eli Lilly Romnia S.R.L.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=RO>Tel: + 40 21 4023000</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eli Lilly and Company (Ireland) Limited</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tel: + 353-(0) 1 661 4377</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=DA>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=RO>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=RO>Eli Lilly farmacevtska druba, d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=RO>Tel: +386 (0)1 580 00 10</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=DA>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>sland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=DA>Icepharma hf.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DA>Smi + 354 540 8000</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=ES-TRAD>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Slovensk republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Eli Lilly Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Tel: </span><span lang=SK>+ 421 220 663 111</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=ES-TRAD>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=FI>Eli Lilly Italia S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tel: + 39- 055 42571</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SV>Oy Eli Lilly Finland Ab </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Puh/Tel: + 358-(0) 9 85 45 250</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Phadisco Ltd </span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EL>&#932;&#951;&#955;</span><span lang=EN-GB>: +357 22 715000</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DE>Eli Lilly Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=DE>Tel: + 46-(0) 8 7378800</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=SV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=LV style='color:black'>Eli Lilly (Suisse) S.A
  P&#257;rst&#257;vniec&#299;ba Latvij&#257;</span><span lang=LV> </span><span
  lang=LV>Tel: </span><b><span lang=NL>+</span></b><span lang=NL>371 67364000</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Eli Lilly and Company Limited</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Tel: + 44-(0) 1256 315000</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last </span><span lang=EN-GB>revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>. </span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection2>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA AND HYPOGLYCAEMIA</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Always carry some sugar (at least
20&nbsp;grams) with you.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Carry some information with you to show you
are diabetic.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA (high blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>If your blood sugar is too high
(hyperglycaemia), you may not have injected enough insulin.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hyperglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have not injected your insulin or not injected enough, or if it has become less
effective, for example through incorrect storage,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
insulin pen does not work properly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>-  you are doing less exercise than usual,
you are under stress (emotional distress, excitement), or you have an injury,
operation, infection or fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>-  you are taking or have taken certain
other medicines (see section 2, &quot;Other medicines and ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Warning
symptoms of hyperglycaemia</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Thirst,
increased need to urinate, tiredness, dry skin, reddening of the face, loss of
appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in
urine. Stomach pain, fast and deep breathing, sleepiness or even loss of
consciousness may be signs of a serious condition (ketoacidosis) resulting from
lack of insulin.</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>What
should you do if you experience hyperglycaemia?</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Test
your blood sugar level and your urine for ketones as soon as any of the above
symptoms occur. </span></b><span lang=EN-GB>Severe hyperglycaemia or
ketoacidosis must always be treated by a doctor, normally in a hospital.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPOGLYCAEMIA (low blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>If your blood sugar level falls too much you may
become unconscious. Serious hypoglycaemia may cause a heart attack or brain
damage and may be life-threatening. You normally should be able to recognise
when your blood sugar is falling too much so that you can take the right
actions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hypoglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
inject too much insulin,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
miss meals or delay them,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
do not eat enough, or eat food containing less carbohydrate than normal (sugar
and substances similar to sugar are called carbohydrates; however, artificial
sweeteners are NOT carbohydrates),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
lose carbohydrates due to vomiting or diarrhoea,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
drink alcohol, particularly if you are not eating much,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are doing more exercise than usual or a different type of physical activity,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an injury or operation or other stress,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an illness or from fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have stopped taking certain other medicines (see section 2,
&quot;Other medicines and ABASAGLAR&quot;).</span></p>

</div>

<div style='border:none;border-right:solid windowtext 1.0pt;padding:0in 1.0pt 0in 0in'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Hypoglycaemia is also more likely to occur if</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have just begun insulin treatment or changed to another insulin preparation
(when changing from your previous basal insulin to ABASAGLAR, hypoglycaemia, if
it occurs, may be more likely to occur in the morning than at night),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
blood sugar levels are almost normal or are unstable,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
change the area of skin where you inject insulin (for example from the thigh to
the upper arm),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
suffer from severe kidney or liver disease, or some other disease such as
hypothyroidism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Warning symptoms of hypoglycaemia</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your body</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that tell you that your
blood sugar level is falling too much or too fast: sweating, clammy skin,
anxiety, fast heart beat, high blood pressure, palpitations and irregular
heartbeat. These symptoms often develop before the symptoms of a low sugar
level in the brain.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your brain</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that indicate a low sugar
level in the brain: headaches, intense hunger, nausea, vomiting, tiredness,
sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in
concentration, impaired reactions, depression, confusion, speech disturbances
(sometimes total loss of speech), visual disorders, trembling, paralysis,
tingling sensations (paraesthesia), numbness and tingling sensations in the area
of the mouth, dizziness, loss of self-control, inability to look after
yourself, convulsions, loss of consciousness.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none;border:none;padding:0in'><span
lang=EN-GB>The first symptoms which alert you to hypoglycaemia (&quot;warning
symptoms&quot;) may change, be weaker or may be missing altogether if</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are elderly, if you have had diabetes for a long time or if you suffer from a
certain type of nervous disease (diabetic autonomic neuropathy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently suffered hypoglycaemia (for example the day before) or if it
develops slowly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have almost normal or, at least, greatly improved blood sugar levels,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently changed from an animal insulin to a human insulin such as ABASAGLAR,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have taken certain other medicines (see section 2, &quot;Other
medicines and ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>In such a case, you may develop severe
hypoglycaemia (and even faint) before you are aware of the problem. Be familiar
with your warning symptoms. If necessary, more frequent blood sugar testing can
help to identify mild hypoglycaemic episodes that may otherwise be overlooked.
If you are not confident about recognising your warning symptoms, avoid
situations (such as driving a car) in which you or others would be put at risk
by hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>What should you do if you experience
hypoglycaemia?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>1. Do not inject insulin. Immediately take about
10 to 20&nbsp;g sugar, such as glucose, sugar cubes or a sugar-sweetened
beverage. Caution: Artificial sweeteners and foods with artificial sweeteners
(such as diet drinks) are of no help in treating hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>2. Then eat something that has a long-acting
effect in raising your blood sugar (such as bread or pasta). Your doctor or
nurse should have discussed this with you previously.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>The recovery of hypoglycaemia may be delayed
because ABASAGLAR has a long action.'</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>3. If the hypoglycaemia comes back again, take
another 10 to 20&nbsp;g sugar.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>4. Speak to a doctor immediately if you are not
able to control the hypoglycaemia or if it recurs. Tell your relatives, friends
and close colleagues the following:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>If you are not able to swallow or if you are
unconscious, you will require an injection of glucose or glucagon (a medicine
which increases blood sugar). These injections are justified even if it is not
certain that you have hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>It is advisable to test your blood sugar
immediately after taking glucose to check that you really have hypoglycaemia.</span></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Package leaflet: Information for the
user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ABASAGLAR 100&nbsp;units/mL KwikPen solution for injection in a
pre-filled pen</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Read all of this leaflet carefully including the Instructions for
Use of the ABASAGLAR KwikPen pre-filled pen, before you start using this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.</span><span lang=EN-GB> This includes any possible
side effects not listed in this leaflet. See section 4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3. How to use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4. Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR contains insulin glargine. This is a modified insulin,
very similar to human insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is used to treat diabetes mellitus in adults, adolescents
and children aged 2&nbsp;years and above.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Diabetes mellitus is a disease where your body does not produce
enough insulin to control the level of blood sugar. Insulin glargine has a long
and steady blood-sugar-lowering action.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are allergic to insulin glargine or any of the other
ingredients of this medicine (listed in section 6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before using ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Follow closely the instructions for posology, monitoring (blood and
urine tests), diet and physical activity (physical work and exercise) as
discussed with your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If your blood sugar is too low (hypoglycaemia), follow the guidance
for hypoglycaemia (see box at the end of this leaflet).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin changes at the injection site</span></i><u><span
lang=EN-GB>.</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The injection site should be rotated to
prevent skin changes such as lumps under the skin. The insulin may not work
well if you inject into a lumpy area (See How to use Abasaglar). Contact your
doctor if you are currently injecting into a lumpy area before you start
injecting into a different area. Your doctor may tell you to check your blood
sugar more closely, and to adjust your insulin or your other antidiabetic
medications dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Travel</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before travelling consult your doctor. You may need to talk about:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the availability of your
insulin in the country you are visiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  supplies of insulin etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  correct storage of your
insulin while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  timing of meals and
insulin administration while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the possible effects of
changing to different time zones,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  possible new health risks
in the countries to be visited,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  what you should do in
emergency situations when you feel unwell or become ill.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Illnesses and injuries</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the following situations, the management of your diabetes may
require a lot of care (for example, adjustment to insulin dose, blood and urine
tests):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are ill or have a
major injury then your blood sugar level may increase (hyperglycaemia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are not eating
enough your blood sugar level may become too low (hypoglycaemia).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In most cases you will need a doctor. <b>Make sure that you contact
a doctor early.</b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have type 1 diabetes (insulin dependent diabetes mellitus),
do not stop your insulin and continue to get enough carbohydrates. Always tell
people who are caring for you or treating you that you require insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin treatment can cause the body to produce antibodies to
insulin (substances that act against insulin). However, only very rarely, this
will require a change to your insulin dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Some patients with long-standing type 2 diabetes mellitus and heart
disease or previous stroke who were treated with pioglitazone and insulin
experienced the development of heart failure. Inform your doctor as soon as
possible if you experience signs of heart failure such as unusual shortness of
breath or rapid increase in weight or localised swelling (oedema).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Insulin mix-ups</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You must always check the </span><span lang=EN-GB>pack and </span><span
lang=EN-GB>insulin label before each injection to avoid mix-ups between
ABASAGLAR and other insulins.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is no experience with the use of ABASAGLAR in children below
the age of 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Some medicines cause changes in the blood sugar level (decrease,
increase or both depending on the situation). In each case, it may be necessary
to adjust your insulin dose to avoid blood sugar levels that are either too low
or too high. Be careful when you start or stop taking another medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines. Before taking a medicine ask your
doctor if it can affect your blood sugar level and what action, if any, you
need to take.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Medicines that may cause your blood sugar level to fall (hypoglycaemia)
include:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>all other medicines to treat diabetes,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>angiotensin converting enzyme (ACE) inhibitors (used to treat
certain heart conditions or high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>disopyramide (used to treat certain heart conditions),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>fluoxetine (used to treat depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>fibrates (used to lower high levels of blood lipids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>monoamine oxidase (MAO) inhibitors (used to treat depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>pentoxifylline, propoxyphene, salicylates (such as aspirin, used to
relieve pain and lower fever), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>somatostatin analogues (such as octreotide, used to treat an
uncommon condition in which you make too much growth hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>sulphonamide antibiotics.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><i><span lang=EN-GB>Medicines that may cause your blood sugar level to
rise (hyperglycaemia) include:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt;font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>corticosteroids (such as &quot;cortisone&quot; used to treat inflammation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt;font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>danazol (medicine acting on ovulation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt;font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>diazoxide (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:10.0pt;font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>diuretics (used to treat high blood pressure or excessive fluid
retention),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>glucagon (pancreas hormone used to treat severe hypoglycaemia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>isoniazid (used to treat tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>oestrogens and progestogens (such as in the contraceptive pill used
for birth control), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>phenothiazine derivatives (used to treat psychiatric disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>somatropin (growth hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>sympathomimetic medicines (such as epinephrine [adrenaline],
salbutamol, terbutaline used to treat asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>thyroid hormones (used to treat thyroid gland disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>atypical antipsychotic medicines (such as clozapine, olanzapine),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>protease inhibitors (used to treat HIV).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Your blood sugar level may either rise or fall if you take:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>beta-blockers (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>clonidine (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>lithium salts (used to treat psychiatric disorders).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pentamidine (used to treat some infections caused by parasites) may
cause hypoglycaemia which may sometimes be followed by hyperglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Beta-blockers like other sympatholytic medicines (such as clonidine,
guanethidine, and reserpine) may weaken or suppress entirely the first warning
symptoms which help you to recognise a hypoglycaemia </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are not sure whether you are taking one of those medicines
ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>ABASAGLAR with alcohol</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your blood sugar levels may either rise or fall if you drink
alcohol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ask your doctor or pharmacist for advice before taking any medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Inform your doctor if you are planning to become pregnant, or if you
are already pregnant. Your insulin dose may need to be changed during pregnancy
and after giving birth. Particularly careful control of your diabetes, and
prevention of hypoglycaemia, is important for the health of your baby.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding consult your doctor as you may require
adjustments in your insulin doses and your diet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your ability to concentrate or react may be reduced if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hypoglycaemia
(low blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hyperglycaemia
(high blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have problems with
your sight.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this possible problem in mind in all situations where you might
put yourself and others at risk (such as driving a car or using machines). You
should contact your doctor for advice on driving if:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  you have frequent episodes of hypoglycaemia,</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  the first warning symptoms which help you to recognise
hypoglycaemia are reduced or absent.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>ABASAGLAR contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>This medicine contains less than 1&nbsp;mmol
(23&nbsp;mg) sodium per dose, which means it is essentially sodium-free.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3. How to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Although ABASAGLAR contains the same active substance as Toujeo
(insulin glargine 300&nbsp;units/mL), these medicines are not interchangeable.
The switch from one insulin therapy to another requires medical prescription,
medical supervision and blood glucose monitoring. Please consult your doctor
for further information.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Dose</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Based on your life-style and the results of your blood sugar
(glucose) tests and your previous insulin usage, your doctor will:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  determine how much ABASAGLAR
per day you will need and at what time,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when to check
your blood sugar level, and whether you need to carry out urine tests,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when you may
need to inject a higher or lower dose of ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is a long-acting insulin. Your doctor may tell you to use
it in combination with a short-acting insulin or with tablets used to treat
high blood sugar levels.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Many factors may influence your blood sugar level. You should know
these factors so that you are able to react correctly to changes in your blood
sugar level and to prevent it from becoming too high or too low. See the box at
the end of this leaflet for further information.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR can be used in adolescents and children aged 2&nbsp;years
and above. Use this medicine exactly as your doctor has told you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Frequency of administration</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You need one injection of ABASAGLAR every day, at the same time of
the day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a
vein, since this will change its action and may cause hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your doctor will show you in which area of the skin you should
inject ABASAGLAR. With each injection, change the puncture site within the
particular area of skin that you are using.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>How to handle ABASAGLAR KwikPen</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR KwikPen is a pre-filled disposable pen containing insulin
glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Read carefully the &quot;</span></b><b><span lang=EN-GB>ABASAGLAR
KwikPen Instructions for Use&quot; included with this package leaflet. You must
use the pen as described in these Instructions for Use.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A new needle must be attached before each use. Only use needles that
are compatible for use with ABASAGLAR KwikPen (see ABASAGLAR KwikPen
Instructions for Use).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A safety test must be performed before each injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Look at the cartridge before you use the pen. Do not use ABASAGLAR
KwikPen if you notice particles in it. Only use ABASAGLAR KwikPen if the
solution is clear, colourless and water-like. Do not shake or mix it before
use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To prevent the possible transmission of disease, each pen must be
used by one patient only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Make sure that neither alcohol nor other disinfectants or other
substances contaminate the insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use a new pen if you notice that your blood sugar control is
unexpectedly getting worse. If you think you may have a problem with ABASAGLAR
KwikPen, consult your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Empty pens must not be re-filled and must be properly discarded.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not use ABASAGLAR KwikPen if it is damaged or not working
properly, it has to be discarded and a new KwikPen has to be used.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you use more ABASAGLAR than you should</span></b><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you <b>have injected
too much ABASAGLAR </b></span><span lang=EN-GB>or are unsure how much you have
injected</span><span lang=EN-GB>,</span><span lang=EN-GB> your blood sugar
level may become too low (hypoglycaemia). Check your blood sugar frequently. In
general, to prevent hypoglycaemia you must eat more food and monitor your blood
sugar. For information on the treatment of hypoglycaemia, see box at the end of
this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you forget to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you have missed a dose
of ABASAGLAR or if you have not injected enough insulin </span><span
lang=EN-GB>or are unsure how much you have injected</span><span lang=EN-GB>, </span><span
lang=EN-GB>your blood sugar level may become too high (hyperglycaemia). Check
your blood sugar frequently. For information on the treatment of
hyperglycaemia, see box at the end of this leaflet.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  Do not take a double dose
to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.55pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>After injecting</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are unsure how much you have injected then check your blood
sugar levels before deciding if you need another injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you stop using ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This could lead to severe hyperglycaemia (very high blood sugar) and
ketoacidosis (build-up of acid in the blood because the body is breaking down
fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who
will tell you what needs to be done.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>If you notice signs of your blood sugar being too low
(hypoglycaemia), </span></b><span lang=EN-GB>take<b> </b>the<b> </b>action to
increase your blood sugar levels <b>immediately</b></span><span lang=EN-GB>. Hypoglycaemia
(low blood sugar) can be very serious and is very common with insulin treatment
(may affect more than 1 in 10 people). Low blood sugar means that there is not
enough sugar in your blood. If your blood sugar level falls too low, you may
pass out (become unconscious). Serious hypoglycaemia may cause brain damage and
may be life-threatening. For more information, see the box at the end of this
leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Severe allergic reactions </span></b><span lang=EN-GB>(rare, may
affect up to 1 in 1,000 people)  the signs </span><span lang=EN-GB>may include
large-scale skin reactions (rash and itching all over the body), severe
swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall
in blood pressure with rapid heartbeat and sweating. Severe allergic reactions
to insulins may become life-threatening. Tell a doctor straight away if you
notice signs of severe allergic reaction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:0in;line-height:normal;page-break-after:avoid;
text-autospace:none'><b><span lang=EN-GB>Skin changes at the injection site </span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>If
you inject insulin too often at the same place, the fatty tissue may shrink
(lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy,
may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up
of a protein called amyloid (cutaneous amyloidosis, how often they occur is not
known). The insulin may not work very well if you inject into a lumpy area. Change
the injection site with each injection to help prevent these skin changes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Common side effects </span></b><span lang=EN-GB>(may
affect up to 1 in 10 people)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;text-autospace:
none'><span lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Skin and allergic reactions at the injection
site</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The signs may include reddening, unusually intense pain when
injecting, itching, hives, swelling or inflammation. They can spread around the
injection site. Most minor reactions to insulins usually disappear in a few
days to a few weeks.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare side effects </span></b><span lang=EN-GB>(may affect up to 1 in
1,000 people)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Eye reactions</span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>A
marked change (improvement or worsening) in your blood sugar control can
disturb your vision temporarily. If you have proliferative retinopathy (an eye
disease related to diabetes) severe hypoglycaemic attacks may cause temporary
loss of vision.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>General disorders</span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB>In rare cases, insulin treatment may also
cause temporary build-up of water in the body, with swelling in the calves and
ankles.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare side-effects </span></b><span lang=EN-GB>(may affect up
to1 in 10,000 people)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In very rare cases, dysgeusia (taste disorders) and myalgia
(muscular pain) can occur.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>In general, the side effects in children and adolescents of 18 years
of age or less are similar to those seen in adults.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Complaints of injection site reactions (injection site pain,
injection site reaction) and skin reactions (rash, urticaria) are reported
relatively more frequently in children and adolescents of 18 years of age or
less than in adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in</span> </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. How to store ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and on the label of the pen after EXP. The expiry date refers to
the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Not in-use pens</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2C - 8C). Do not freeze. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not put ABASAGLAR next to the freezer compartment or a freezer
pack.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep the pre-filled pen in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>In-use pens</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pre-filled pens in use or carried as a spare may be stored for a
maximum of 28&nbsp;days up to 30C and away from direct heat or direct light.
The pen in use must not be stored in the refrigerator. Do not use it after this
time period. The pen cap must be put back on the pen after each injection in
order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The active substance is
insulin glargine. Each millilitre of the solution contains 100&nbsp;units of
the active substance insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The other ingredients
are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 ABASAGLAR
contains sodium), hydrochloric acid and water for injections.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR 100&nbsp;units/mL solution for injection in a pre-filled
pen, KwikPen, is a clear and colourless solution.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR is
available in packs containing 5 pre&#8209;filled pens and in multipacks
comprising 2&nbsp;cartons, each containing 5&nbsp;pre&#8209;filled pens.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim,
France.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Eli Lilly Benelux
  S.A./N.V.</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=NL>Tl/Tel: + 32-(0)2 548 84 84</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=SV>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=SV>Eli Lilly </span><span lang=BG style='color:black'>Lietuva</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=LT>Tel. +370 (5) 2649600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1058;&#1055;
  &quot;&#1045;&#1083;&#1080; &#1051;&#1080;&#1083;&#1080;
  &#1053;&#1077;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&quot;
  &#1041;.&#1042;. - &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=BG>&#1090;&#1077;&#1083;.
  +359 2 491 41 40</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly
  Benelux S.A./N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tl/Tel: +
  32-(0)2 548 84 84</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:56.5pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=CS>ELI LILLY
  &#268;R, s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 420 234
  664 111</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarorszg</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Lilly Hungria Kft.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 36 1
  328 5100</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly
  Danmark A/S </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: +45 45 26
  60 00</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Charles de
  Giorgio Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 356 25600
  500</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Lilly Deutschland
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel. + 49-(0)
  6172 273 2222</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Eli Lilly
  Nederland B.V. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 31-(0) 30
  60 25 800</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Eli Lilly
  Nederland B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel</span><span
  lang=ET>: </span><span lang=EN-GB>+372 6 817 280</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Eli Lilly
  Norge A.S. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Tlf: + 47 22
  88 18 00</span></p>
  <p class=PIbodytext><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL style='layout-grid-mode:
  line'>&#934;&#913;&#929;&#924;&#913;&#931;&#917;&#929;&#914;-&#923;&#921;&#923;&#923;&#933;
  &#913;.&#917;.&#914;.&#917;. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL style='layout-grid-mode:
  line'>&#932;&#951;&#955;: +30 210 629 4600</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Eli Lilly
  Ges.m.b.H. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: + 43-(0) 1
  711 780</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES-TRAD>Espaa</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Lilly S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: + 34-91 663
  50 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=ES>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Eli Lilly Polska
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel: </span><span
  lang=EN-GB>+48 22 440 33 00</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Lilly France SAS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tl: +33-(0) 1 55
  49 34 34</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Lilly Portugal
  Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +
  351-21-4126600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Eli Lilly
  Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385 1
  2350 999</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Romnia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Eli Lilly Romnia
  S.R.L.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Tel: + 40 21
  4023000</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=DA style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly and
  Company (Ireland) Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353-(0)
  1 661 4377</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=RO>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Eli Lilly
  farmacevtska druba, d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Tel: +386 (0)1
  580 00 10</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>sland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=DA>Icepharma hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Smi + 354 540
  8000</span></p>
  <p class=PIbodytext><span lang=ES-TRAD>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Slovensk republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Eli Lilly Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Tel: </span><span lang=SK>+ 421 220 663 111</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES-TRAD>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FI>Eli Lilly Italia
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 39- 055
  42571</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Oy Eli Lilly
  Finland Ab </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Puh/Tel: +
  358-(0) 9 85 45 250</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phadisco Ltd </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=EN-GB>: +357 22 715000</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Eli Lilly Sweden
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: + 46-(0) 8
  7378800</span></p>
  <p class=PIbodytext><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV style='color:
  black'>Eli Lilly (Suisse) S.A P&#257;rst&#257;vniec&#299;ba Latvij&#257;</span><span
  lang=LV> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: </span><b><span
  lang=NL>+</span></b><span lang=NL>371 67364000</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly and
  Company Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 44-(0)
  1256 315000</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last </span><span lang=EN-GB>revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>. </span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection4>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA AND HYPOGLYCAEMIA</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Always carry some sugar (at least
20&nbsp;grams) with you.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Carry some information with you to show you
are diabetic.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA (high blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>If your blood sugar is too high
(hyperglycaemia), you may not have injected enough insulin.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hyperglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have not injected your insulin or not injected enough, or if it has become less
effective, for example through incorrect storage,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
insulin pen does not work properly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>- </span><span lang=EN-GB> you are doing
less exercise than usual, you are under stress (emotional distress,
excitement), or you have an injury, operation, infection or fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>-  you are taking or have taken certain
other medicines (see section 2, &quot;Other medicines and ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Warning
symptoms of hyperglycaemia</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Thirst,
increased need to urinate, tiredness, dry skin, reddening of the face, loss of
appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in
urine. Stomach pain, fast and deep breathing, sleepiness or even loss of
consciousness may be signs of a serious condition (ketoacidosis) resulting from
lack of insulin.</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>What
should you do if you experience hyperglycaemia?</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Test
your blood sugar level and your urine for ketones as soon as any of the above
symptoms occur. </span></b><span lang=EN-GB>Severe hyperglycaemia or ketoacidosis
must always be treated by a doctor, normally in a hospital.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPOGLYCAEMIA (low blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>If your blood sugar level falls too much you may
become unconscious. Serious hypoglycaemia may cause a heart attack or brain
damage and may be life-threatening. You normally should be able to recognise
when your blood sugar is falling too much so that you can take the right
actions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hypoglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
inject too much insulin,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
miss meals or delay them,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
do not eat enough, or eat food containing less carbohydrate than normal (sugar
and substances similar to sugar are called carbohydrates; however, artificial
sweeteners are NOT carbohydrates),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
lose carbohydrates due to vomiting or diarrhoea,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
drink alcohol, particularly if you are not eating much,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are doing more exercise than usual or a different type of physical activity,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an injury or operation or other stress,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an illness or from fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have stopped taking certain other medicines (see section 2,
&quot;Other medicines and ABASAGLAR&quot;).</span></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Hypoglycaemia is also more likely to occur if</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have just begun insulin treatment or changed to another insulin preparation
(when changing from your previous basal insulin to ABASAGLAR, hypoglycaemia, if
it occurs, may be more likely to occur in the morning than at night),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
blood sugar levels are almost normal or are unstable,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
change the area of skin where you inject insulin (for example from the thigh to
the upper arm),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
suffer from severe kidney or liver disease, or some other disease such as
hypothyroidism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Warning symptoms of hypoglycaemia</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your body</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that tell you that your
blood sugar level is falling too much or too fast: sweating, clammy skin,
anxiety, fast heart beat, high blood pressure, palpitations and irregular
heartbeat. These symptoms often develop before the symptoms of a low sugar
level in the brain.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your brain</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that indicate a low sugar
level in the brain: headaches, intense hunger, nausea, vomiting, tiredness,
sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in
concentration, impaired reactions, depression, confusion, speech disturbances
(sometimes total loss of speech), visual disorders, trembling, paralysis,
tingling sensations (paraesthesia), numbness and tingling sensations in the
area of the mouth, dizziness, loss of self-control, inability to look after
yourself, convulsions, loss of consciousness.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none;border:none;padding:0in'><span
lang=EN-GB>The first symptoms which alert you to hypoglycaemia (&quot;warning
symptoms&quot;) may change, be weaker or may be missing altogether if</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are elderly, if you have had diabetes for a long time or if you suffer from a
certain type of nervous disease (diabetic autonomic neuropathy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently suffered hypoglycaemia (for example the day before) or if it
develops slowly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have almost normal or, at least, greatly improved blood sugar levels,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently changed from an animal insulin to a human insulin such as ABASAGLAR,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have taken certain other medicines (see section 2, &quot;Other
medicines and ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>In such a case, you may develop severe
hypoglycaemia (and even faint) before you are aware of the problem. Be familiar
with your warning symptoms. If necessary, more frequent blood sugar testing can
help to identify mild hypoglycaemic episodes that may otherwise be overlooked.
If you are not confident about recognising your warning symptoms, avoid
situations (such as driving a car) in which you or others would be put at risk
by hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>What should you do if you experience hypoglycaemia?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>1. Do not inject insulin. Immediately take about
10 to 20&nbsp;g sugar, such as glucose, sugar cubes or a sugar-sweetened
beverage. Caution: Artificial sweeteners and foods with artificial sweeteners
(such as diet drinks) are of no help in treating hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>2. Then eat something that has a long-acting
effect in raising your blood sugar (such as bread or pasta). Your doctor or
nurse should have discussed this with you previously.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>The recovery of hypoglycaemia may be delayed
because ABASAGLAR has a long action.'</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>3. If the hypoglycaemia comes back again, take
another 10 to 20&nbsp;g sugar.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>4. Speak to a doctor immediately if you are not
able to control the hypoglycaemia or if it recurs. Tell your relatives, friends
and close colleagues the following:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>If you are not able to swallow or if you are
unconscious, you will require an injection of glucose or glucagon (a medicine
which increases blood sugar). These injections are justified even if it is not
certain that you have hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>It is advisable to test your blood sugar
immediately after taking glucose to check that you really have hypoglycaemia.</span></p>

</div>

<b><span style='font-size:18.0pt;font-family:"Arial",sans-serif'><br clear=all
style='page-break-before:always'>
</span></b>

<p class=MsoHeading7 align=center style='margin-top:6.0pt;text-align:center'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Instructions for use</span></p>

<p class=MsoHeading7 align=center style='margin-top:6.0pt;text-align:center'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>ABASAGLAR </span><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>100&nbsp;units/mL
KwikPen solution for injection in a pre-filled pen</span></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b>i</b><b><span
lang=EN-GB>nsulin glargine </span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
line-height:13.0pt'><span lang=EN-GB><img border=0 width=624 height=101
id="Picture 210" src="ABASAGLAR_clean_files/image008.png"></span></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
style='position:relative;z-index:251714560'><span style='left:0px;position:
absolute;left:1px;top:-31401px;width:604px;height:1px'><img width=604 height=1
src="ABASAGLAR_clean_files/image009.png"></span></span><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<br clear=ALL>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:red'>PLEASE READ THESE INSTRUCTIONS BEFORE USE</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Read the instructions for use before you start taking ABASAGLAR and
each time you get another ABASAGLAR KwikPen. There may be new information. This
information does not take the place of<b> </b>talking to your healthcare
professional about your medical condition or your treatment.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt'><span lang=EN-GB>ABASAGLAR KwikPen
(Pen) is a disposable pen containing 300&nbsp;units (3&nbsp;mL) of insulin
glargine. You can give yourself multiple doses using one pen. The pen dials
1&nbsp;unit at a time. You can give from 1 to 60 <span style='background:lightgrey'>80</span>&nbsp;units
in a single injection. <b>If your dose is more than 60 <span style='background:
lightgrey'>80</span> units, you will need to give yourself more than one
injection. </b>The plunger only moves a little with each injection and you may
not notice that it moves. The plunger will only reach the end of the cartridge
when you have used all 300 units in the pen.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Do not share your pen with other people, even if the needle has been
changed. Do not reuse or share needles with other people. You may give an
infection to them or get an infection from them.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This pen is not
recommended for use by the blind or visually impaired without the help of
someone trained to use the pen.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB><img border=0
width=624 height=164 id="Picture 209" src="ABASAGLAR_clean_files/image010.png"></span></p>

<p class=MsoNormal style='line-height:12.0pt'><span lang=EN-GB><img border=0
width=624 height=197 id="Picture 208" src="ABASAGLAR_clean_files/image011.png"></span></p>

<p class=MsoNormal><b><span style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span style='layout-grid-mode:line'>How to recognise your
ABASAGLAR KwikPen</span></b><b><span lang=EN-GB style='font-family:"Arial",sans-serif'>:</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Pen colour:  Light grey</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Dose Knob:  Light grey with green ring on
the end</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Labels:   Light grey with green colour
bars</span></p>

<p class=MsoHeader style='margin-top:6.0pt'><span lang=EN-GB style='font-size:
11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<h5 style='text-align:justify;text-justify:inter-ideograph;background:transparent'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>Supplies
needed to give your injection:</span></h5>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ABASAGLAR KwikPen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>KwikPen compatible needle (BD [Becton, Dickinson
and Company] pen needles recommended). </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Swab</span></p>

<p class=MsoNormal>&nbsp;</p>

<h5 style='background:transparent'><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>Preparing </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:windowtext'>your
Pen</span></h5>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wash your hands with soap and water</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Check the pen to make sure you are taking the
right type of insulin. This is especially important if you use more than 1 type
of insulin.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not</span></b><span lang=EN-GB> use your pen
past the expiration date printed on the label or for more than 28 days after
you first start using the pen.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always use a <b>new needle</b> for each
injection to help prevent infections and blocked needles.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeader style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt;line-height:13.0pt'><span lang=EN-GB><img
border=0 width=624 height=559 id="Picture 207"
src="ABASAGLAR_clean_files/image012.png"></span></p>

<h5 style='background:transparent'><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>Priming your pen</span></h5>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Prime before each injection.</span></b><span
lang=EN-GB> </span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal;text-autospace:none'><span
     lang=EN-GB>Priming your pen means removing the air from the needle and
     cartridge that may collect during normal use and ensures that the pen is
     working correctly</span><span lang=EN-GB>. </span></li>
 <li class=MsoNormal style='line-height:normal;text-autospace:none'><span
     lang=EN-GB>If you <b>do not</b> prime before each injection, you may get
     too much or too little insulin.</span></li>
</ul>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt'><span lang=EN-GB style='layout-grid-mode:
line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB><img border=0
width=624 height=546 id="Picture 206" src="ABASAGLAR_clean_files/image013.png"></span></p>

<h5 style='background:transparent'><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;color:windowtext'>Selecting your dose</span></h5>

<p class=IFUBulletedBodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol;color:windowtext'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:windowtext'>You can give from 1 to 60<span style='background:lightgrey'>80</span>&nbsp;units
in a single injection.</span></p>

<p class=IFUBulletedBodyText style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol;color:windowtext'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif;
color:windowtext'>If your dose is more than 60<span style='background:lightgrey'>80</span>
units, you will need to give more than one injection.</span></p>

<p class=IFUBulletedBodyText2 style='margin-left:42.55pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif;color:windowtext'> If
you need help deciding how to divide up your dose, ask your healthcare professional.</span></p>

<p class=IFUBodyText style='margin-left:42.55pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'> You should use a new
needle for each injection and repeat the priming step.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;text-autospace:none'><span
lang=EN-GB><img border=0 width=644 height=576 id="Picture 205"
src="ABASAGLAR_clean_files/image014.png"></span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The pen will not let you dial more than the
number of units left in the pen.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you need to inject more than the number of
units left in the pen, you may either:</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-14.2pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>- inject the amount left in
your pen and then use a new pen to give the rest of your dose, <b>or</b></span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-14.2pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>- get a new pen and inject the
full dose.</span><span lang=EN-GB style='font-family:"Arial",sans-serif'> </span></p>

<p class=MsoListParagraph style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is normal to see a small amount of insulin
left in the pen that you cannot inject.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoHeading8><span style='font-family:"Times New Roman",serif'>Giving
your injection</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inject your insulin as your healthcare
professional has shown you.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Change (rotate) your injection site for each
injection.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not</span></b><span lang=EN-GB> try to
change your dose while injecting.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:0in;
margin-left:.25in;margin-bottom:.0001pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB><img border=0
width=624 height=858 id="Picture 204" src="ABASAGLAR_clean_files/image015.png"></span></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoHeading8><span style='font-family:"Times New Roman",serif'>After
your injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB><img border=0
width=624 height=446 id="Picture 203" src="ABASAGLAR_clean_files/image016.png"></span></p>

<p class=TableText style='margin-top:0in;text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Disposing of pens and needles</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Put used needles in a closable,
puncture-resistant sharps container. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not recycle the filled sharps container.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Ask your healthcare professional about options
to dispose of the pens and sharps container properly.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The directions regarding needle handling are not
intended to replace local, healthcare professional or institutional policies.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TableText style='margin-top:0in;text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Storing your pen</span></b></p>

<p class=TableText style='text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Unused pens</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store unused pens in the refrigerator at
2&nbsp;&nbsp;C to 8&nbsp;&nbsp;C.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not</span></b><span lang=EN-GB> freeze
ABASAGLAR. <b>Do not</b> use if it has been frozen.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Unused pens may be used until the expiration
date printed on the label, if the pen has been kept in the refrigerator.</span></p>

<p class=TableText style='text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>In-use pen</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store the pen you are currently using at room
temperature [below 30&nbsp;&nbsp;C] and away from heat and light.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Throw away the pen you are using after 28&nbsp;days,
even if it still has insulin left in it. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TableText style='margin-top:0in;text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>General information about the safe and effective use of your pen</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Keep your pen and needles out of the sight
and reach of children. </span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not</span></b><span lang=EN-GB> use your pen
if any part looks broken or damaged.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always carry an extra pen in case yours is lost
or damaged.</span></p>

<p class=TableText style='text-align:justify;text-justify:inter-ideograph;
page-break-after:auto'><b><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:windowtext'>Troubleshooting</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you cannot remove the pen cap, gently twist
the cap back and forth, and then pull the cap straight off.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:28.35pt;text-indent:
-28.35pt;line-height:normal;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If the dose knob it is hard to push:</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:56.7pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB>- Pushing the dose
knob more slowly will make it easier to inject.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:56.7pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB>- Your needle may be
blocked. Put on a new needle and prime the pen.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:56.7pt;text-indent:-28.35pt;
line-height:normal;text-autospace:none'><span lang=EN-GB>- You may have dust,
food, or liquid inside the pen. Throw the pen away and get a new pen.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have any questions or problems with your ABASAGLAR KwikPen,
contact your healthcare professional for assistance.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><b><span lang=EN-GB>This leaflet was last </span><span
lang=EN-GB>revised in </span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='margin-top:14.0pt;margin-right:6.0pt;
margin-bottom:11.0pt;margin-left:6.35pt;text-align:center;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal;
text-autospace:none'><b><span lang=EN-GB>Package leaflet: Information for the
user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ABASAGLAR 100&nbsp;units/mL Tempo Pen solution for injection in a
pre-filled pen</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>insulin glargine</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Read all of this leaflet carefully including the Instructions for
Use of the ABASAGLAR Tempo pre-filled pen, before you start using this medicine
because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor, pharmacist or nurse.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:-.1pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them, even if their signs of illness
are the same as yours.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:28.35pt;text-indent:-28.35pt;
line-height:normal'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.</span><span lang=EN-GB> This includes any possible
side effects not listed in this leaflet. See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>3. How to use ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>4. Possible side effects </span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>5. How to store ABASAGLAR</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>1. What ABASAGLAR is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR contains insulin glargine. This is a modified insulin,
very similar to human insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is used to treat diabetes mellitus in adults, adolescents
and children aged 2&nbsp;years and above.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Diabetes mellitus is a disease where your body does not produce
enough insulin to control the level of blood sugar. Insulin glargine has a long
and steady blood-sugar-lowering action.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>2. What you need to know before you use ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not use
ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are allergic to insulin glargine or any of the other
ingredients of this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Warnings and
precautions </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Talk to your doctor, pharmacist or nurse before using ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Follow closely the instructions for posology, monitoring (blood and
urine tests), diet and physical activity (physical work and exercise) as
discussed with your doctor.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If your blood sugar is too low (hypoglycaemia), follow the guidance
for hypoglycaemia (see box at the end of this leaflet).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin changes at the injection site</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The injection site should be rotated to
prevent skin changes such as lumps under the skin. The insulin may not work
well if you inject into a lumpy area (See How to use Abasaglar). Contact your
doctor if you are currently injecting into a lumpy area before you start
injecting into a different area. Your doctor may tell you to check your blood
sugar more closely, and to adjust your insulin or your other antidiabetic
medications dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Travel</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Before travelling consult your doctor. You may need to talk about:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the availability of your
insulin in the country you are visiting,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  supplies of insulin etc.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  correct storage of your
insulin while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  timing of meals and
insulin administration while travelling,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  the possible effects of
changing to different time zones,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  possible new health risks
in the countries to be visited,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  what you should do in
emergency situations when you feel unwell or become ill.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Illnesses and injuries</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In the following situations, the management of your diabetes may
require a lot of care (for example, adjustment to insulin dose, blood and urine
tests):</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are ill or have a
major injury then your blood sugar level may increase (hyperglycaemia).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you are not eating
enough your blood sugar level may become too low (hypoglycaemia).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In most cases you will need a doctor. <b>Make sure that you contact
a doctor early.</b></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have type&nbsp;1 diabetes (insulin dependent diabetes
mellitus), do not stop your insulin and continue to get enough carbohydrates.
Always tell people who are caring for you or treating you that you require
insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Insulin treatment can cause the body to produce antibodies to
insulin (substances that act against insulin). However, only very rarely, this
will require a change to your insulin dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Some patients with long-standing type&nbsp;2 diabetes mellitus and
heart disease or previous stroke who were treated with pioglitazone and insulin
experienced the development of heart failure. Inform your doctor as soon as
possible if you experience signs of heart failure such as unusual shortness of
breath or rapid increase in weight or localised swelling (oedema).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><a
name="_Hlk38985814"><i><span lang=EN-GB>Insulin mix-ups</span></i></a></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>You must always check the pack and the insulin label before each
injection to avoid mix-ups between ABASAGLAR and other insulins.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Tempo Pen</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The Tempo Pen
contains a magnet. If you have a medical device fitted, such as a heart
pacemaker, this may not work correctly if the Tempo Pen is held too close. </span><span
lang=EN-GB>T</span><span lang=EN-GB>he magnetic field extends to approximately 1.5&nbsp;cm</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Children</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>There is no experience with the use of ABASAGLAR in children below
the age of 2&nbsp;years.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other medicines and ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Some medicines cause changes in the blood sugar level (decrease,
increase or both depending on the situation). In each case, it may be necessary
to adjust your insulin dose to avoid blood sugar levels that are either too low
or too high. Be careful when you start or stop taking another medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Tell your doctor or pharmacist if you are taking, have recently
taken or might take any other medicines. Before taking a medicine ask your
doctor if it can affect your blood sugar level and what action, if any, you
need to take.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Medicines that may cause your blood sugar level to fall
(hypoglycaemia) include:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>all other medicines to treat diabetes,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>angiotensin converting enzyme (ACE) inhibitors (used to treat
certain heart conditions or high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>disopyramide (used to treat certain heart conditions),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>fluoxetine (used to treat depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>fibrates (used to lower high levels of blood lipids),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>monoamine oxidase (MAO) inhibitors (used to treat depression),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>pentoxifylline, propoxyphene, salicylates (such as aspirin, used to
relieve pain and lower fever), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>somatostatin analogues (such as octreotide, used to treat an
uncommon condition in which you make too much growth hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>sulphonamide antibiotics.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Medicines that may cause your blood sugar level to rise
(hyperglycaemia) include:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>corticosteroids (such as &quot;cortisone&quot; used to treat
inflammation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>danazol (medicine acting on ovulation),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>diazoxide (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>diuretics (used to treat high blood pressure or excessive fluid
retention),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>glucagon (pancreas hormone used to treat severe hypoglycaemia),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>isoniazid (used to treat tuberculosis),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>oestrogens and progestogens (such as in the contraceptive pill used
for birth control), </span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>phenothiazine derivatives (used to treat psychiatric disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>somatropin (growth hormone),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>sympathomimetic medicines (such as epinephrine [adrenaline],
salbutamol, terbutaline used to treat asthma),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>thyroid hormones (used to treat thyroid gland disorders),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>atypical antipsychotic medicines (such as clozapine, olanzapine),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>protease inhibitors (used to treat HIV).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><i><span
lang=EN-GB>Your blood sugar level may either rise or fall if you take:</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>beta-blockers (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>clonidine (used to treat high blood pressure),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:10.0pt;
font-family:"Courier New"'><span style='font:7.0pt "Times New Roman"'></span><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-GB>lithium salts (used to treat psychiatric disorders).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pentamidine (used to treat some infections caused by parasites) may
cause hypoglycaemia which may sometimes be followed by hyperglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Beta-blockers like other sympatholytic medicines (such as clonidine,
guanethidine, and reserpine) may weaken or suppress entirely the first warning
symptoms which help you to recognise a hypoglycaemia </span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you are not sure whether you are taking one of those medicines
ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>ABASAGLAR with alcohol</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your blood sugar levels may either rise or fall if you drink
alcohol.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Ask your doctor or pharmacist for advice before taking any medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Inform your doctor if you are planning to become pregnant, or if you
are already pregnant. Your insulin dose may need to be changed during pregnancy
and after giving birth. Particularly careful control of your diabetes, and
prevention of hypoglycaemia, is important for the health of your baby.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are breast-feeding consult your doctor as you may require
adjustments in your insulin doses and your diet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your ability to concentrate or react may be reduced if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hypoglycaemia
(low blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have hyperglycaemia
(high blood sugar levels),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  you have problems with
your sight.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this possible problem in mind in all situations where you might
put yourself and others at risk (such as driving a car or using machines). You
should contact your doctor for advice on driving if:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  you have frequent episodes of hypoglycaemia,</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  the first warning symptoms which help you to recognise
hypoglycaemia are reduced or absent.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>ABASAGLAR contains sodium</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>This medicine contains less than 1&nbsp;mmol
(23&nbsp;mg) sodium per dose, which means it is essentially sodium-free.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>3. How to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use this medicine exactly as your doctor has told you. Check
with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Although ABASAGLAR contains the same active substance as Toujeo
(insulin glargine 300&nbsp;units/mL), these medicines are not interchangeable.
The switch from one insulin therapy to another requires medical prescription,
medical supervision and blood glucose monitoring. Please consult your doctor
for further information.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Dose</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Based on your life-style and the results of your blood sugar
(glucose) tests and your previous insulin usage, your doctor will:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  determine how much
ABASAGLAR per day you will need and at what time,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when to check
your blood sugar level, and whether you need to carry out urine tests,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  tell you when you may
need to inject a higher or lower dose of ABASAGLAR.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is a long-acting insulin. Your doctor may tell you to use
it in combination with a short-acting insulin or with tablets used to treat
high blood sugar levels.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Many factors may influence your blood sugar level. You should know
these factors so that you are able to react correctly to changes in your blood
sugar level and to prevent it from becoming too high or too low. See the box at
the end of this leaflet for further information.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR can be used in adolescents and children aged 2&nbsp;years
and above. Use this medicine exactly as your doctor has told you.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Frequency of administration</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>You need one injection of ABASAGLAR every day, at the same time of
the day.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a
vein, since this will change its action and may cause hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Your doctor will show you in which area of the skin you should
inject ABASAGLAR. With each injection, change the puncture site within the
particular area of skin that you are using.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>How to handle ABASAGLAR Tempo Pen</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR Tempo Pen is a pre-filled disposable pen containing
insulin glargine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Read carefully the &quot;</span></b><b><span lang=EN-GB>ABASAGLAR Tempo
Pen Instructions for Use&quot; included with this package leaflet. You must use
the pen as described in these Instructions for Use.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A new needle must be attached before each use. Only use needles that
are compatible for use with ABASAGLAR Tempo Pen (see ABASAGLAR Tempo Pen
Instructions for Use).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>A safety test must be performed before each injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Look at the cartridge before you use the pen. Do not use ABASAGLAR Tempo
Pen if you notice particles in it. Only use ABASAGLAR Tempo Pen if the solution
is clear, colourless and water-like. Do not shake or mix it before use.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>To prevent the possible transmission of disease, each pen must be
used by one patient only.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Make sure that neither alcohol nor other disinfectants or other substances
contaminate the insulin.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Always use a new pen if you notice that your blood sugar control is
unexpectedly getting worse. If you think you may have a problem with ABASAGLAR Tempo
Pen, consult your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Empty pens must not be re-filled and must be properly discarded.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not use ABASAGLAR Tempo Pen if it is damaged or not working
properly, it has to be discarded and a new Tempo Pen has to be used.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoCommentText><a name="_Hlk56610361"><span lang=EN-GB
style='font-size:11.0pt'>The Tempo Pen is designed to work with the Tempo Smart
Button.</span></a><span lang=EN-GB style='font-size:11.0pt'> The optional
additional feature Tempo Smart Button is a product available for the Tempo Pen,
which may be used for transmitting dose information to a mobile application.
The Tempo Pen can be used with or without the Tempo Smart Button attached. See
instructions provided with the Tempo Smart Button and the mobile application
for further information. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you use more ABASAGLAR than you should</span></b><b><span
lang=EN-GB> </span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you <b>have injected
too much ABASAGLAR </b></span><span lang=EN-GB>or are unsure how much you have
injected</span><b><span lang=EN-GB>,</span></b><span lang=EN-GB>, your blood
sugar level may become too low (hypoglycaemia). Check your blood sugar
frequently. In general, to prevent hypoglycaemia you must eat more food and
monitor your blood sugar. For information on the treatment of hypoglycaemia,
see box at the end of this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you forget to use ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  If you have missed a dose
of ABASAGLAR or if you have not injected enough insulin </span><span
lang=EN-GB>or are unsure how much you have injected</span><span lang=EN-GB>,
your blood sugar level may become too high (hyperglycaemia). Check your blood
sugar frequently. For information on the treatment of hyperglycaemia, see box
at the end of this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>-  Do not take a double dose to make up for a forgotten dose.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:.55pt;line-height:normal;page-break-after:
avoid'><b><span lang=EN-GB>After injecting</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you are unsure how much you have injected then check your blood
sugar levels before deciding if you need another injection.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>If you stop using ABASAGLAR</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>This could lead to severe hyperglycaemia (very high blood sugar) and
ketoacidosis (build-up of acid in the blood because the body is breaking down
fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who
will tell you what needs to be done.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you have any further questions on the use of this medicine, ask
your doctor, pharmacist or nurse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>4. Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>Like all medicines, this medicine can cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>If you notice signs of your blood sugar being too low
(hypoglycaemia), </span></b><span lang=EN-GB>take<b> </b>the<b> </b>action to
increase your blood sugar levels <b>immediately</b></span><span lang=EN-GB>. Hypoglycaemia
(low blood sugar) can be very serious and is very common with insulin treatment
(may affect more than 1 in 10&nbsp;people). Low blood sugar means that there is
not enough sugar in your blood. If your blood sugar level falls too low, you
may pass out (become unconscious). Serious hypoglycaemia may cause brain damage
and may be life-threatening. For more information, see the box at the end of
this leaflet.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><b><span
lang=EN-GB>Severe allergic reactions </span></b><span lang=EN-GB>(rare, may
affect up to 1 in 1,000&nbsp;people)  the signs </span><span lang=EN-GB>may
include large-scale skin reactions (rash and itching all over the body), severe
swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall
in blood pressure with rapid heartbeat and sweating. Severe allergic reactions
to insulins may become life-threatening. Tell a doctor straight away if you
notice signs of severe allergic reaction.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Skin changes at the injection site</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>If you inject insulin too often at the same place, the fatty
tissue may shrink (lipoatrophy, may affect up to 1 in 100&nbsp;people) or
thicken (lipohypertrophy, may affect up to 1 in 10&nbsp;people). Lumps under
the skin may also be caused by build-up of a protein called amyloid (cutaneous
amyloidosis, how often they occur is not known). The insulin may not work very
well if you inject into a lumpy area. Change the injection site with each
injection to help prevent these skin changes.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Common side effects </span></b><span lang=EN-GB>(may
affect up to 1 in 10&nbsp;people)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;page-break-after:
avoid;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Skin and allergic reactions at the injection
site</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The signs may include reddening, unusually intense pain when
injecting, itching, hives, swelling or inflammation. They can spread around the
injection site. Most minor reactions to insulins usually disappear in a few
days to a few weeks.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Rare side effects </span></b><span lang=EN-GB>(may affect up to 1 in
1,000&nbsp;people)</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Eye reactions</span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-GB>A
marked change (improvement or worsening) in your blood sugar control can
disturb your vision temporarily. If you have proliferative retinopathy (an eye
disease related to diabetes) severe hypoglycaemic attacks may cause temporary
loss of vision.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>General disorders</span></b></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;line-height:normal;
text-autospace:none'><span lang=EN-GB>In rare cases, insulin treatment may also
cause temporary build-up of water in the body, with swelling in the calves and
ankles.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Very rare side-effects </span></b><span lang=EN-GB>(may affect up
to1 in 10,000&nbsp;people)</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>In very rare cases, dysgeusia (taste disorders) and myalgia
(muscular pain) can occur.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>Use in children and adolescents</span></b></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>In general, the side effects in children and adolescents of 18&nbsp;years
of age or less are similar to those seen in adults.</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Complaints of injection site reactions (injection site pain,
injection site reaction) and skin reactions (rash, urticaria) are reported
relatively more frequently in children and adolescents of 18&nbsp;years of age
or less than in adults.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Reporting of
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. You can also
report side effects directly via <span style='background:lightgrey'>the
national reporting system listed in</span> </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:windowtext;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>. By reporting side effects you can help provide more information on
the safety of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>5. How to store ABASAGLAR</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep this medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not use this medicine after the expiry date which is stated on
the carton and on the label of the pen after EXP. The expiry date refers to
the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>Not in-use pens</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Store in a refrigerator (2&nbsp;C&nbsp;&nbsp;8&nbsp;C). Do not freeze.
</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not put ABASAGLAR next to the freezer compartment or a freezer
pack.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Keep the pre-filled pen in the outer carton in order to protect from
light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><u><span
lang=EN-GB>In-use pens</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Pre-filled pens in use or carried as a spare may be stored for a
maximum of 28&nbsp;days up to 30&nbsp;C and away from direct heat or direct
light. The pen in use must not be stored in the refrigerator. Do not use it
after this time period. The pen cap must be put back on the pen after each
injection in order to protect from light.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use. These
measures will help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>6. Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR contains</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The active substance is
insulin glargine. Each millilitre of the solution contains 100&nbsp;units of
the active substance insulin glargine (equivalent to 3.64&nbsp;mg).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The other ingredients
are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section&nbsp;2
ABASAGLAR contains sodium), hydrochloric acid and water for injections.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>-  The Tempo Pen contains a
magnet <a name="_Hlk45788345">(see section&nbsp;2, &quot;Warnings and
precautions&quot;).</a></span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
lang=EN-GB>What ABASAGLAR looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>ABASAGLAR <a name="_Hlk44089800">100&nbsp;units/m</a>L solution for
injection in a pre-filled pen, Tempo Pen, is a clear and colourless solution. </span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ABASAGLAR is
available in packs containing 5&nbsp;pre&#8209;filled pens and in multipacks
comprising 2&nbsp;cartons, each containing 5&nbsp;pre&#8209;filled pens.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Marketing Authorisation Holder </span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The
Netherlands.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim,
France.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>For any information about this medicine, please contact the local representative
of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Eli Lilly Benelux
  S.A./N.V.</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=NL>Tl/Tel: + 32-(0)2 548 84 84</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=SV>Lietuva</span></b></p>
  <p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
  lang=SV>Eli Lilly </span><span lang=BG style='color:black'>Lietuva</span></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=LT>Tel. +370 (5) 2649600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=SV>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><b><span
  lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG>&#1058;&#1055;
  &quot;&#1045;&#1083;&#1080; &#1051;&#1080;&#1083;&#1080;
  &#1053;&#1077;&#1076;&#1077;&#1088;&#1083;&#1072;&#1085;&#1076;&quot;
  &#1041;.&#1042;. - &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=BG>&#1090;&#1077;&#1083;.
  +359 2 491 41 40</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly
  Benelux S.A./N.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tl/Tel: +
  32-(0)2 548 84 84</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:56.5pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=CS>ELI LILLY
  &#268;R, s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 420 234
  664 111</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:56.5pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarorszg</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Lilly Hungria Kft.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 36 1
  328 5100</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly
  Danmark A/S </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: +45 45 26
  60 00</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Charles de
  Giorgio Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 356 25600
  500</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Lilly Deutschland
  GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel. + 49-(0)
  6172 273 2222</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Eli Lilly
  Nederland B.V. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: + 31-(0) 30
  60 25 800</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=SV style='color:black'>Eli Lilly Nederland
  B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel</span><span
  lang=ET>: </span><span lang=EN-GB>+372 6 817 280</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Eli Lilly
  Norge A.S. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NO-NYN>Tlf: + 47 22
  88 18 00</span></p>
  <p class=PIbodytext><span lang=NL>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EL>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL style='layout-grid-mode:
  line'>&#934;&#913;&#929;&#924;&#913;&#931;&#917;&#929;&#914;-&#923;&#921;&#923;&#923;&#933;
  &#913;.&#917;.&#914;.&#917;. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL style='layout-grid-mode:
  line'>&#932;&#951;&#955;: +30 210 629 4600</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Eli Lilly
  Ges.m.b.H. </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ET>Tel: + 43-(0) 1
  711 780</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES-TRAD>Espaa</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Lilly S.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=ES>Tel: + 34-91 663
  50 00</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=ES-TRAD>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Eli Lilly Polska
  Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PL>Tel: </span><span
  lang=EN-GB>+48 22 440 33 00</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Lilly France SAS</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FR>Tl: +33-(0) 1 55
  49 34 34</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=FR>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=PT>Lilly Portugal
  Produtos Farmacuticos, Lda</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=NL>Tel: +
  351-21-4126600</span></p>
  <p class=PIbodytext style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Eli Lilly
  Hrvatska d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: +385 1
  2350 999</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Romnia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Eli Lilly Romnia
  S.R.L.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Tel: + 40 21
  4023000</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'><span
  lang=DA style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
  clear=all style='page-break-before:always'>
  </span>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly and
  Company (Ireland) Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353-(0)
  1 661 4377</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=RO>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Eli Lilly
  farmacevtska druba, d.o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=RO>Tel: +386 (0)1
  580 00 10</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>sland</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  text-autospace:none'><span lang=DA>Icepharma hf.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DA>Smi + 354 540
  8000</span></p>
  <p class=PIbodytext><span lang=ES-TRAD>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=DA>Slovensk republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Eli Lilly Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=SK>Tel: </span><span lang=SK>+ 421 220 663 111</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=ES-TRAD>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=FI>Eli Lilly Italia
  S.p.A.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 39- 055
  42571</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=SV>Oy Eli Lilly
  Finland Ab </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Puh/Tel: +
  358-(0) 9 85 45 250</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Phadisco Ltd </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EL>&#932;&#951;&#955;</span><span
  lang=EN-GB>: +357 22 715000</span></p>
  <p class=PIbodytext><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=DA>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Eli Lilly Sweden
  AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=DE>Tel: + 46-(0) 8
  7378800</span></p>
  <p class=PIbodytext><b><span lang=SV>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=SV>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV style='color:
  black'>Eli Lilly (Suisse) S.A P&#257;rst&#257;vniec&#299;ba Latvij&#257;</span><span
  lang=LV> </span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=LV>Tel: </span><b><span
  lang=NL>+</span></b><span lang=NL>371 67364000</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Eli Lilly and
  Company Limited</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 44-(0)
  1256 315000</span></p>
  <p class=PIbodytext><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last </span><span lang=EN-GB>revised in </span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>Other sources of information</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Detailed information on this medicine is available on the European
Medicines Agency web site: </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/"><span style='color:windowtext'>http://www.ema.europa.eu</span></a></span><span
lang=EN-GB>. </span></p>

</div>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection5>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA AND HYPOGLYCAEMIA</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Always carry some sugar (at least
20&nbsp;grams) with you.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Carry some information with you to show you
are diabetic.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPERGLYCAEMIA (high blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>If your blood sugar is too high
(hyperglycaemia), you may not have injected enough insulin.</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hyperglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have not injected your insulin or not injected enough, or if it has become less
effective, for example through incorrect storage,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
insulin pen does not work properly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>- </span><span lang=EN-GB> you are doing
less exercise than usual, you are under stress (emotional distress,
excitement), or you have an injury, operation, infection or fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><span lang=EN-GB>-  you are taking or have taken certain
other medicines (see section&nbsp;2, &quot;Other medicines and
ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Warning
symptoms of hyperglycaemia</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>Thirst,
increased need to urinate, tiredness, dry skin, reddening of the face, loss of
appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in
urine. Stomach pain, fast and deep breathing, sleepiness or even loss of
consciousness may be signs of a serious condition (ketoacidosis) resulting from
lack of insulin.</span></p>

<p class=MsoNormal style='border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>What
should you do if you experience hyperglycaemia?</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>Test
your blood sugar level and your urine for ketones as soon as any of the above
symptoms occur. </span></b><span lang=EN-GB>Severe hyperglycaemia or ketoacidosis
must always be treated by a doctor, normally in a hospital.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>HYPOGLYCAEMIA (low blood sugar levels)</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>If your blood sugar level falls too much you may
become unconscious. Serious hypoglycaemia may cause a heart attack or brain
damage and may be life-threatening. You normally should be able to recognise
when your blood sugar is falling too much so that you can take the right
actions.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Why does hypoglycaemia occur?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples include:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
inject too much insulin,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
miss meals or delay them,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
do not eat enough, or eat food containing less carbohydrate than normal (sugar
and substances similar to sugar are called carbohydrates; however, artificial
sweeteners are NOT carbohydrates),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
lose carbohydrates due to vomiting or diarrhoea,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
drink alcohol, particularly if you are not eating much,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are doing more exercise than usual or a different type of physical activity,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an injury or operation or other stress,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are recovering from an illness or from fever,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have stopped taking certain other medicines (see section 2,
&quot;Other medicines and ABASAGLAR&quot;).</span></p>

</div>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 1.0pt 1.0pt 1.0pt'>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Hypoglycaemia is also more likely to occur if</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have just begun insulin treatment or changed to another insulin preparation
(when changing from your previous basal insulin to ABASAGLAR, hypoglycaemia, if
it occurs, may be more likely to occur in the morning than at night),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  your
blood sugar levels are almost normal or are unstable,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
change the area of skin where you inject insulin (for example from the thigh to
the upper arm),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
suffer from severe kidney or liver disease, or some other disease such as
hypothyroidism.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>Warning symptoms of hypoglycaemia</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your body</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that tell you that your
blood sugar level is falling too much or too fast: sweating, clammy skin,
anxiety, fast heart beat, high blood pressure, palpitations and irregular
heartbeat. These symptoms often develop before the symptoms of a low sugar
level in the brain.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><i><span lang=EN-GB>- In your brain</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>Examples of symptoms that indicate a low sugar
level in the brain: headaches, intense hunger, nausea, vomiting, tiredness,
sleepiness, sleep disturbances, restlessness, aggressive behaviour, lapses in
concentration, impaired reactions, depression, confusion, speech disturbances
(sometimes total loss of speech), visual disorders, trembling, paralysis,
tingling sensations (paraesthesia), numbness and tingling sensations in the
area of the mouth, dizziness, loss of self-control, inability to look after
yourself, convulsions, loss of consciousness.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
line-height:normal;text-autospace:none;border:none;padding:0in'><span
lang=EN-GB>The first symptoms which alert you to hypoglycaemia (&quot;warning
symptoms&quot;) may change, be weaker or may be missing altogether if</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are elderly, if you have had diabetes for a long time or if you suffer from a
certain type of nervous disease (diabetic autonomic neuropathy),</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently suffered hypoglycaemia (for example the day before) or if it
develops slowly,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have almost normal or, at least, greatly improved blood sugar levels,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
have recently changed from an animal insulin to a human insulin such as
ABASAGLAR,</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none;border:none;padding:0in'><span lang=EN-GB>-  you
are taking or have taken certain other medicines (see section&nbsp;2,
&quot;Other medicines and ABASAGLAR&quot;).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>In such a case, you may develop severe
hypoglycaemia (and even faint) before you are aware of the problem. Be familiar
with your warning symptoms. If necessary, more frequent blood sugar testing can
help to identify mild hypoglycaemic episodes that may otherwise be overlooked.
If you are not confident about recognising your warning symptoms, avoid
situations (such as driving a car) in which you or others would be put at risk
by hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><b><span lang=EN-GB>What should you do if you experience
hypoglycaemia?</span></b></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>1. Do not inject insulin. Immediately take about
10 to 20&nbsp;g sugar, such as glucose, sugar cubes or a sugar-sweetened
beverage. Caution: Artificial sweeteners and foods with artificial sweeteners
(such as diet drinks) are of no help in treating hypoglycaemia.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>2. Then eat something that has a long-acting
effect in raising your blood sugar (such as bread or pasta). Your doctor or
nurse should have discussed this with you previously.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>The recovery of hypoglycaemia may be delayed
because ABASAGLAR has a long action.'</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>3. If the hypoglycaemia comes back again, take
another 10 to 20&nbsp;g sugar.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>4. Speak to a doctor immediately if you are not
able to control the hypoglycaemia or if it recurs. Tell your relatives, friends
and close colleagues the following:</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><a name="_Hlk57019084"><span lang=EN-GB>If you are not able to
swallow or if you are unconscious, you will require an injection of glucose or
glucagon (a medicine which increases blood sugar). These injections are
justified even if it is not certain that you have hypoglycaemia.</span></a></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none;border:none;
padding:0in'><span lang=EN-GB>It is advisable to test your blood sugar
immediately after taking glucose to check that you really have hypoglycaemia.</span></p>

</div>

<b><span style='font-size:18.0pt;font-family:"Arial",sans-serif'><br clear=all
style='page-break-before:always'>
</span></b>

<p class=MsoHeading7 align=center style='margin-top:6.0pt;text-align:center'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black'>Instructions
for use</span></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>ABASAGLAR 100units/mL Tempo Pen solution for
injection in a pre-filled pen</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>insulin glargine </span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><b><span
lang=EN-GB style='color:black'>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center'><span
style='position:relative;z-index:251717632'><span style='left:0px;position:
absolute;left:47px;top:-46214px;width:509px;height:1px'><img width=509
height=1 src="ABASAGLAR_clean_files/image017.jpg"
alt="Chart&#10;&#10;Description automatically generated"></span></span><span
lang=EN-GB style='color:black'>&nbsp;</span></p>

<br clear=ALL>

<p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
lang=EN-GB style='color:red'>PLEASE READ THESE INSTRUCTIONS BEFORE USE</span></b></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>Read
the instructions for use before you start using ABASAGLAR and each time you get
another ABASAGLAR Tempo Pen. There may be new information. This information
does not take the place of talking to your healthcare professional about your
medical condition or your treatment.</span></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>ABASAGLAR
Tempo Pen (Pen) is a disposable prefilled pen containing 300&nbsp;units (3&nbsp;mL)
of insulin glargine. You can give yourself multiple doses using one pen. The pen
dials 1&nbsp;unit at a time. You can give from 1 to 80&nbsp;units in a single
injection. <b>If your dose is more than 80&nbsp;units, you will need to give
yourself more than one injection.</b> The plunger only moves a little with each
injection, and you may not notice that it moves. The plunger will only reach
the end of the cartridge when you have used all 300&nbsp;units in the </span><span
style='font-family:"Times New Roman",serif'>pen.</span></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=mdTblEntry style='line-height:normal'><span lang=EN-GB
style='font-size:11.0pt'>The Tempo Pen is designed to work with the Tempo Smart
Button. The Tempo Smart Button is an optional product that can be attached to
the Tempo Pen dose knob and aids in transmitting Abasaglar dose information
from the Tempo Pen to a compatible mobile application. The Tempo Pen injects
insulin with or without the Tempo Smart Button attached. Your Smart Button must
be attached to a Tempo Pen to record or transfer dose data. Push the Smart
Button straight down on the dose knob until you hear a snap or feel the Smart
Button snap into place. To transmit data to the mobile application, follow the
instructions provided with the Tempo Smart Button and the instructions with the
mobile application</span><span style='font-size:11.0pt'>.</span></p>

<p class=mdTblEntry style='text-align:justify;text-justify:inter-ideograph;
line-height:normal'><span style='font-size:11.0pt'>&nbsp;</span></p>

<p class=IFUBodyText style='margin-top:0in'><b><span style='font-family:"Times New Roman",serif'>Do
not share your pen with other people, even if the needle has been changed. Do
not reuse or share needles with other people. You may give an infection to them
or get an infection from them.</span></b></p>

<p class=IFUBodyText style='margin-top:0in'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>This
pen is not recommended for use by the blind or visually impaired without the
help of someone trained to use the pen.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoHeader style='margin-top:6.0pt;page-break-after:avoid'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB><img border=0
width=624 height=187 id="Picture 202" src="ABASAGLAR_clean_files/image018.png"></span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
12.0pt'><img border=0 width=624 height=180 id="Picture 201"
src="ABASAGLAR_clean_files/image019.png"></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>How to recognise your ABASAGLAR
Tempo pen:</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Pen colour: Light grey</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Dose Knob: Light grey</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Labels: Light grey with green
colour bars</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>Supplies needed to give your
injection:</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Tempo Pen containing your
insulin</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Tempo Pen compatible needle (BD
[Becton, Dickinson and Company] pen needles recommended)</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Swab</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'>Needles and swab are not included.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>Preparing your pen</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Wash your hands with soap and
water.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Check the pen to make sure
you are taking the right type of insulin. This is especially important if you
use more than 1 type of insulin.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> <b>Do not</b> use your pen past
the expiration date printed on the pen label or for more than 28&nbsp;days
after you first start using the pen.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:17.85pt;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Always use a <b>new needle</b>
for each injection to help prevent infections and blocked needles.</span></p>

<p class=MsoHeader style='margin-top:6.0pt'><span style='font-size:11.0pt;
color:black'>&nbsp;</span></p>

<p class=IFUHeading1 style='margin-top:0in;line-height:12.0pt'><span
style='layout-grid-mode:both'><img border=0 width=624 height=588
id="Picture 200" src="ABASAGLAR_clean_files/image020.png"></span></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Priming your pen</span></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Prime before each injection.</span></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Priming
your pen means removing the air from the needle and cartridge that may collect
during normal use and ensures that the pen is working correctly.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> If
you <b>do not</b> prime before each injection, you may get too much or too
little insulin.</span></p>

<p class=MsoHeader style='margin-top:6.0pt;page-break-after:avoid'><span
style='font-size:11.0pt;color:black'>&nbsp;</span></p>

<p class=IFUBulletedBodyText style='margin-left:.25in;line-height:12.0pt'><img
border=0 width=624 height=535 id="Picture 199"
src="ABASAGLAR_clean_files/image021.png"></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>Selecting your dose</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> You can give from 1 to
80&nbsp;units in a single injection.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> If your dose is more than
80&nbsp;units, you will need to give more than one injection.</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> </span><span style='font-family:
"Times New Roman",serif'>If you need help deciding how to divide up your dose,
ask your healthcare professional.</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> You should use a new needle
for each injection and repeat the priming step.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt;line-height:
12.0pt'><img border=0 width=677 height=502 id="Picture 198"
src="ABASAGLAR_clean_files/image022.png"></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> The pen will not let you dial
more than the number of units left in the pen.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> If you need to inject more
than the number of units left in the pen, you may either:</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> inject the amount left in your
pen and then use a new pen to give the rest of your dose, <b>or</b></span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> get a new pen and inject the
full dose.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> It is normal to see a small
amount of insulin left in the pen that you cannot inject.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>Giving your injection</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><b><span
style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Inject your insulin as your healthcare
professional has shown you.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> Change (rotate) your
injection site for each injection.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-17.85pt'><span
style='font-family:"Times New Roman",serif'> <b>Do not</b> try to change
your dose while injecting.</span></p>

<p class=IFUBulletedBodyText style='margin-left:.25in'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB><img border=0
width=624 height=445 id="Picture 194" src="ABASAGLAR_clean_files/image023.png"></span><b><span
lang=EN-GB>After your injection</span></b></p>

<p class=MsoNormal><span style='position:relative;z-index:251716608'><span
style='position:absolute;left:433px;top:-50052px;width:148px;height:1px'><img
width=148 height=1 src="ABASAGLAR_clean_files/image024.jpg" alt=Step5a></span></span><span
lang=EN-GB>&nbsp;</span></p>

<br clear=ALL>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt;line-height:12.0pt'><img border=0
width=624 height=420 id="Picture 193" src="ABASAGLAR_clean_files/image025.png"></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>Disposing
of pens and needles</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Put
used needles in a closable, puncture-resistant sharps container.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> <b>Do
not</b> recycle the filled sharps container.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Ask
your healthcare professional about options to dispose of the pens and sharps
container properly.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> The
directions regarding needle handling are not intended to replace local,
healthcare professional or institutional policies.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>Storing
your pen</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Unused pens</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Store
unused pens in the refrigerator at (2&nbsp;C to 8&nbsp;C).</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> <b>Do
not</b> freeze ABASAGLAR. <b>Do not</b> use if it has been frozen.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Unused
pens may be used until the expiration date printed on the label, if the pen has
been kept in the refrigerator.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=IFUHeading1 style='margin-top:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>In-use pen</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Store
the pen you are currently using at room temperature [below (30&nbsp;C)] and
away from dust, food and liquids, heat and light.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB> Throw away the pen you are using after 28&nbsp;days,
even if it still has insulin left in it.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><b><span lang=EN-GB>General information about the safe and effective
use of your pen</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> <b>Keep
your pen and needles out of the sight and reach of children.</b></span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> <b>Do
not</b> use your pen if any part looks broken or damaged.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> Always
carry an extra pen in case yours is lost or damaged.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>Troubleshooting</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><b><span style='font-family:"Times New Roman",serif'>&nbsp;</span></b></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> If
you cannot remove the pen cap, gently twist the cap back and forth, and then
pull the cap straight off.</span></p>

<p class=IFUBulletedBodyText style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:.25in;margin-bottom:.0001pt'><span style='font-family:"Times New Roman",serif'> If
the dose knob is hard to push:</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in'><span style='font-family:
"Times New Roman",serif'> Pushing the dose knob more slowly will make it
easier to inject.</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in'><span style='font-family:
"Times New Roman",serif'> Your needle may be blocked. Put on a new needle
and prime the pen.</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in'><span style='font-family:
"Times New Roman",serif'> You may have dust, food, or liquid inside the pen.
Throw the pen away and get a new pen. You may need to get a prescription from
your healthcare professional.</span></p>

<p class=IFUBulletedBodyText2 style='margin-top:0in'><span style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>If
you have any questions or problems with your ABASAGLAR Tempo Pen, contact your
healthcare professional for help.</span></p>

<p class=IFUBodyText style='margin-top:0in'><span style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;text-align:justify;text-justify:
inter-ideograph;line-height:normal'><b><span lang=EN-GB>This leaflet was last </span><span
lang=EN-GB>revised in </span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
